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Abstract 
 
Neuroblastoma is the most common extra cranial solid tumor of childhood, originating from the 
neural crest progenitors primed for sympathoadrenal differentiation. Phenotypically, as well as 
clinically, the tumor shows a considerable and variable heterogeneity. Several genetic 
aberrations have been found to correlate with poor clinical outcome in neuroblastoma, the most 
important of which is the amplification of the MYCN locus that occurs in roughly 20% of 
primary tumors and is strongly correlated with advanced stage disease and treatment failure. 
Another feature related to patient survival is the degree of tumor cell differentiation, which 
ranges from small, undifferentiated cells in aggressive tumors to well differentiated non-dividing 
cells in tumors, which are considered benign. These evidences suggest that neuroblastoma could 
originate from an impaired capacity of the neural crest cells already committed to the 
sympathoadrenal final phenotype to respond to signals or to lack signals operating during this 
differentiation program. Therefore, molecular modulators able to force differentiation may be 
effective in the treatment of this pathology. Arginine methylation has been shown to regulate 
differentiation of a well-known number of cell lineages. In particular, it has been demonstrated 
that the coactivator-associated arginine methyltransferase 1 (CARM1) can negatively regulate 
the process of neuronal differentiation by methylating the RNA-binding protein HuD, a known 
determinant of the neuronal phenotype. 
Our data demonstrate that CARM1 stable silencing produces a significant neurite extension and 
branching in SK-N-BE(2) neuroblastoma cells. This morphological evidence has been confirmed 
at the molecular level by a microarray analysis, adding further clues. Although not demonstrated 
yet, we can speculate that CARM1 effects are due at least partially to changes in HuD 
methylation level that in turn modulates its mRNA target binding capability and reduces the 
differentiative potential of neuroblastoma cells. Indeed, we demonstrated that protein levels of 
CARM1 and HuC and HuD proteins remarkably covary in a panel of 17 neuroblastoma cell 
lines, suggesting that an increase in CARM1 expression could be effectively an HuD 
neutralizing event with respect to differentiation of neuroblastoma cells. Furthermore, HuD 
interaction with CARM1 was verified through a pull-down assay. 
If our hypothesis will be verified, we could speculate that CARM1, acting on HuD methylation, 
can interfere in further differentiation of neuroblastoma cells. Thus, CARM1 could be 
considered, and then employed, as a potential druggable target in neuroblastoma therapy. 
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1.1 Biology of neuroblastoma  
Neuroblastoma, a tumor originating from primitive cells of the sympathetic nervous system, is 
the most common extra cranial solid tumor of childhood, with an annual incidence of about 
1.500 cases in Europe and 700 cases in US and Canada per year, representing about 30% of all 
cancers diagnosed in European and US infants. The median age at the moment of diagnosis is 
approximately 18 months, with over 1/3 diagnosed at less than 1 year of age (Brodeur, 2003). 
Neuroblastoma arises from the neural crest cells of the sympathetic nervous system (Fig. 1.1A 
and Fig. 1.1B), an embryonic cell population originating in the ectoderm at the margins of the 
neural tube that, after a phase of epithelial-to-mesenchymal transition (EMT), starts its migration 
to generate the craniofacial cartilage and bone, the smooth muscle cells of the cardiovascular 
system, and the majority of the peripheral nervous system, such as the peripheral and enteric 
neurons, the adrenal chromaffin cells and the peripheral glia, plus other non-neural cell types, 
such as the melanocytes (Sauka-Spengler & Bronner-Fraser, 2008). As a consequence, 
neuroblastoma can develop anywhere in the sympathetic nervous system.  
Around 65% of primary neuroblastoma tumors are found in the abdomen, whereas other 
common sites of disease are the neck, the chest and the pelvis. Due to the heterogeneity of the 
tumor and the different sites of localization, the symptoms are vague (fatigue, loss of appetite, 
fever and joint pain are highly common) and very variable, depending on the site of the primary 
tumor and the presence or absence of metastasis, usually in the distant lymph nodes, bone 
marrow, bone, liver, or other organs (Pizzo P. A., Poplack D. G. editors. 5th ed. Philadelphia, 
PA), resulting difficult to be diagnosed at an early stage. In this context, neuroblastoma is listed 
in the larger group of neuroblastic tumors, which are heterogeneous in terms of biological, 
genetic and morphological characteristics. They have three unique alternative phenotypic 
behaviors: they can spontaneously regress, they can mature or they can aggressively proliferate. 
The evidence of a naturally occurring programmed cell death fate supports spontaneous 
regression during normal embryonic life, especially in the development of the central and 
peripheral nervous system. This process is referred as “involution” (SHIMADA et al., 1999), it 
was described early in the last century and later defined as the clinical entity of Stage 4S 
(Special) disease from the International Neuroblastoma Staging System (INSS, G. M. Brodeur et 
al., 1994). Spontaneous regression has not yet been fully understood, but evidences suggest that 
specific genetic traits, such an intact short arm of chromosome 1 and the absence of MYCN gene 
amplification, support this condition. Despite most neuroblastomas appear as undifferentiated 
tumors, consisting of small, round cells with little or any evidence of neural differentiation 
(probably because of their derivation from the sympathoadrenal progenitors), some types of 
neuroblastoma show a partial histological differentiation and are called ganglioneuroblastomas. 
The most differentiated end of the spectrum is called ganglioneuroma, which consists of clusters 
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of mature neurons surrounded by Schwann cells. Unfortunately, the majority of neuroblastomas 
at the time of diagnosis present an advanced stage of disease, and they do not undergo regression 
or maturation (Stages 3 or 4 of the INSS). Moreover, it is well established a correlation between 
tumor aggressive proliferation and the presence of MYCN gene amplification, as well as 
deletion of 1p and 11p and gain of 17q (see 1.3; Perez et al., 2000, Spitz et al., 2002, Bown, 
1999).  
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1.2 Prognostic considerations 
The two most important clinical variables in predicting patient outcome are the age of patient at 
the moment of diagnosis and the stage of the disease. 
The role of age in neuroblastoma risk stratification is fundamental: it has been analyzed as a 
binary variable, with 18 months used as the age cut point in most risk stratification matrices. 
Although the reason is not still clear, children younger than 18 months of age have higher 
chances for a favorable outcome, even in tumors with MYCN amplification. Metastatic 
neuroblastoma in children older than 18 months at diagnosis is lethal for most patients despite 
aggressive multimodality therapy (Fig.1.2; Modak & Cheung, 2010). 
 
 
 
Fig.1.2. Overall survival for children with MYCN-non-amplified stage 4 neuroblastoma (Modak & 
Cheung, 2010).  
 
 
In 1989 the International Neuroblastoma Staging System (INSS) was established and it is 
currently used to stage neuroblastoma patients (Brodeur et al., 1994). This system ranks patients 
in six stages depending on the localization of the tumor and its state of progression (Fig.1.3). 
Stage 1 gathers patients with localized tumor that can be removed completely by surgery. In 
Stages 2A and 2B patients bear tumors that are confined but cannot be completely removed 
through surgery.  
Children with tumors in the middle of the chest or abdomen or that are spread to both left and 
right sides of the body are grouped in Stage 3.  
 10 
In Stage 4 patients, the primary tumor has spread to distant lymph nodes, bone, bone marrow, 
liver, skin, and/or other organs.  
Patients in stage 4S are less than 12 months of age and carry a localized primary tumor that has 
spread only to the skin, liver, or bone marrow. These tumors (about 5% of cases), as previously 
said, often undergo spontaneous regression or differentiation (i.e. into a ganglioneuroma) 
without any treatment (Maris et al., 2007). 
 
 
 
 
 
Fig.1.3. International Neuroblastoma Staging System (INSS) allows classification of 
neuroblastoma depending on the localization of the tumor at the moment of diagnosis (i =liver; 
ii = bone marrow; iii = bone; iv = lymph nodes; v = skin). (Modified hand drawing, by C. P. 
Reynolds MD PhD, University of Southern California). 
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1.3 Genetic and biological markers 
In the last decade many genetic features of neuroblastoma have been found to correlate with 
clinical outcome, for example ploidy status, oncogene amplification and allelic loss. These 
biological markers have been evaluated to determine their value in assigning prognosis, and 
some of these have been incorporated into the strategies used for risk assignment. 
The genetic aberration most consistently associated with poor outcome in neuroblastoma is 
MYCN amplification, which is defined as ≥ 10 copies per diploid genome. Genetic amplification 
of MYCN is never manifested at the 2p23-24 resident site of the gene itself, but is found in 
homogeneously staining regions (HSRs) on other chromosomes, or in extra-chromosomal 
double-minute chromatin bodies (DMs). This gene is amplified in approximately 25% of de 
novo cases and is more common in patients with advanced-stage disease. Patients whose tumors 
have MYCN amplification tend to have rapid tumor progression and a poor prognosis, even in 
the setting of other favorable factors such as low-stage disease or 4S disease (Perez et al., 2000). 
The reason why MYCN amplification is associated with a more aggressive phenotype is still 
uncertain.  
 
Deletions of the short arm of chromosome 1 lead to loss of heterozygosity (LOH) and can be 
identified in 25–35% of neuroblastomas. The gene or genes within chromosome 1p involved in 
the pathogenesis of neuroblastoma have not been identified, despite intensive investigation. 
Whether the loss of heterozygosity due to deletion of alleles from 1p is an independent indicator 
of prognosis remains controversial. However, clear evidence suggests that allelic loss at 1p36 
predicts an increased risk of relapse in patients with localized tumors (Spitz et al.; 2002). 
 
Both MYCN amplification and deletion of chromosome 1p are strongly correlated with a poor 
outcome and with each other, therefore it is controversial whether they are independent 
prognostic variables (White et al., 2005). Nevertheless, they seem to characterize a genetically 
distinct subset of highly aggressive neuroblastomas. Most cases with MYCN amplification also 
have 1p loss but not all cases with 1p loss have MYCN amplification, indicating that 1p deletion 
might precede the development of amplification. Indeed, it might be necessary to delete a gene 
that regulates MYCN expression, or one that mediates programmed cell death in the presence of 
high MYCN gene expression, for amplification to occur. Alternatively, there might be an 
underlying genetic abnormality that leads to genomic instability that predisposes to both 1p loss 
and MYCN amplification (Brodeur, 2003). 
Allelic loss of long arm of chromosome 11 (11q) is present in 35–45% of primary tumors (Spitz 
et al., 2002). This genomic aberration is inversely correlated with 1p deletion and MYCN 
amplification. Interestingly, 11q loss is associated with decreased event-free survival, but only in 
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patients lacking MYCN amplification. When the two abnormalities occur together, the prognostic 
impact of MYCN amplification is dominant, nevertheless loss of 11q might prove to be a useful 
predictor of outcome in clinically high-risk patients without MYCN amplification (Brodeur, 
2003). 
 
The other specific karyotypic abnormality that has been detected so far is trisomy of the long 
arm of chromosome 17 (17q). Allelotyping, CGH and array-CGH studies have indicated that this 
abnormality might occur in more than half of all neuroblastomas. Although unbalanced gain of 
17q can occur independently, it frequently takes place through balanced translocation with 
chromosome 1 or 11 (Bown, 1999). The 17q breakpoints vary, but gain of a region 17q22-qter 
suggests that a dosage effect of one or more genes provides a selective advantage 
(Schleiermacher et al., 2004). The gene (or genes) responsible for the selective advantage is 
unknown, but overexpression of survivin — a member of the IAPs (inhibitor of apoptosis 
proteins) — has been proposed (Islam et al.; 2000). Gain of 17q is associated with more 
aggressive neuroblastomas, although its prognostic significance relative to other genetic and 
biological markers awaits a large prospective trial and multivariate analysis. 
 
DNA index is another useful marker that correlates with response to therapy for patients younger 
than 2 years who have disseminated disease (Bagatell et al., 2005). The DNA content of 
neuroblastomas falls into two broad categories: near diploid or hyperdiploid (often near triploid). 
It was demonstrated that infants whose neuroblastoma have hyperdiploidy (DNA index >1) have 
a good therapeutic response to cyclophosphamide and doxorubicin (Look et al., 1991). In 
contrast, infants whose tumors have a DNA index of about 1 are less responsive to the latter 
combination and require more aggressive therapy. Genetic models of neuroblastoma suggest that 
less aggressive tumors have a fundamental defect in mitosis associated with whole chromosome 
gains and losses, which could explain why near-triploidy seems to be favorable. Conversely, 
more malignant neuroblastomas have a fundamental defect in genomic stability, resulting in the 
so-called segmental aberration genotype, composed of chromosomal rearrangements, 
unbalanced translocations, and maintenance of a near-diploid DNA content (Maris et al., 2007). 
 
To summarize, the accumulated research on the genetics of neuroblastoma indicates that there 
are at least two genetic subsets of neuroblastoma that are highly predictive of clinical behavior. 
The classification takes into account abnormalities of 1p, MYCN copy number and DNA content. 
The first subset is characterized by mitotic dysfunction, which leads to hyperdiploid or near-
triploid modal karyotype. These tumors lack MYCN amplification, 1p loss or 17q gain. The 
patients are generally less than 1 year of age with localized disease and a very good prognosis. 
 13 
The second type is characterized by gross chromosomal aberrations and a near-diploid 
karyotype. Within this type, two subsets can be distinguished. One is characterized by 11q 
deletion and lack of both MYCN amplification and 1p loss. Patients are usually older, with more 
advanced stages of disease that is slowly progressive and often fatal. The other subset, more 
aggressive, has MYCN amplification and 1p loss. These patients are generally between 1 and 
5 years of age, with advanced-stage, rapidly progressive disease that is frequently fatal (Brodeur, 
2003). 
 
In 2009 the International Neuroblastoma Risk Group (INRG) task force proposed a new pre-
treatment classification system that takes into account biological markers such as MYCN 
amplification, DNA index, and chromosome 11q status in addition to age and stage (Modak & 
Cheung, 2010). 
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1.4 Neuroblastoma treatments and differentiation therapy 
 
Different treatments can be applied on children with neuroblastoma, according to the risk-group 
assigned to the tumor.  
Surgery is commonly used to remove the tumor as well as any lymph nodes nearby the tumor. If 
tumor is localized and has not spread to other parts of the body, surgery represents the only 
treatment needed.  
If tumor has spread, the combination with other treatments, such as chemotherapy, radiation 
therapy, bone marrow transplantation, immunotherapy and differentiating agents is required 
(Wagner & Danks, 2009). 
The use of neural differentiation-inducing agents appears to be an attractive treatment for 
neuroblastoma pathology. As described previously, this tumor has embryonic features, 
presumably as a consequence of misregulated differentiation programs during the development 
of the sympathoadrenal lineage of nervous system. Therefore, molecular modulators able to 
induce differentiation can be effective in the treatment of this malignancy. 
Several agents have been reported to induce differentiation in neuroblastoma cell line models, 
including 12-O-TetradecanoylPhorbol-13-Acetate (TPA) and Herbimycin A. However, the best 
characterized differentiation inducers for neuroblastoma are represented by retinoids (Seeger & 
Haussler, 1983). Retinoids, which are vitamin A derivatives, have been shown to be fundamental 
in nervous system development and maintenance (Ross et al., 2000). In vitro, retinoids induce 
differentiation and growth arrest of malignant neuroblastoma cells probably through binding to 
retinoid acid receptors (Thiele, 1998). Intracellular retinol is metabolized to all-trans retinoic 
acids, which then activates a number of nuclear receptors that heterodimerize and regulate gene 
transcription. In addition, it has been shown that all-trans retinoic acid promotes the neuronal 
phenotype in neuroblastoma cells, inducing neurite outgrowth and a reduction of cell 
proliferation (Christie et al., 2008). 
Consistent with these findings, the results of independent trials have demonstrated that the 
administration of retinoic acid significantly improves the overall survival rates after bone-
marrow transplantation. 
However, approximately 50% of patients develop resistance or are unresponsive to 
differentiation therapy (Marrow, 1999). For this reason, a particular attention is actually given to 
the investigation of new molecules that are able to induce differentiation of neuroblastoma cells, 
in combination with, or alternative to, the use of retinoids. 
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2.1 Protein arginine methylation 
The primary sequence of a protein is determined by the coding sequence present in the 
corresponding gene, but its functional diversity is then extended by several posttranslational 
modifications, such as phosphorylation, acetylation, glycosylation, methylation and 
ubiquitylation. These covalent modifications modulate the activity of most eukaryotic proteins, 
influencing almost all the aspects of normal cell biology and pathogenesis (Berger, 2002). 
Although phosphorylation has been the most widely studied posttranslational modification, 
recent studies have indicated an emerging and central role of protein methylation in different 
cellular processes, including gene transcription, RNA metabolism, signal transduction and 
neuronal differentiation (Cimato et al., 1997; Aletta et al., 1998; Gary & Clarke, 1998). 
Arginine methylation is a common posttranslational modification of mainly nuclear proteins in 
eukaryotic cells, and the recent discovery of the enzyme family of the protein arginine 
methyltransferases (PRMTs) have made in this process PRMTs of particular interest.  
PRMTs catalyze the addition of one or two methyl groups from the S-adenosylmethionine 
(AdoMet) to arginine residues, generating three possible products (Fig. 2.1): 
 
- Monomethylarginine 
- NG, NG-dimethylarginine, in which both methyl groups are on the same nitrogen (aDMA, 
asymmetric dimethylarginine). 
- NG, N'G-dimethylarginine, in which each nitrogen atom receives one methyl group (sDMA, 
symmetric dimethylarginine). 
 
Nine PRMTs have been identified in mammals (Pahlich et al., 2006). According to the 
methylated form of arginine residues of their substrates, PMRTs are classified in two categories: 
type I enzymes (PRMT1, PRMT2, PRMT3, PRMT4/CARM1, PRMT6 and PRMT8) catalyze 
the formation of monomethylarginine and aDMA, while type II enzymes (PRMT5, PRMT7 and 
PRMT9) catalyze the formation of monomethylarginine and sDMA (Fig. 2.2). Other enzymes 
have been recently proposed as PMRTs, but their activities still requires a validation. PRMTs are 
co-activators/co-repressors of several nucleic acid-binding proteins, affecting protein-DNA or 
protein-RNA interactions. 
Histones are the main PRMT targets (Di Lorenzo & Bedford, 2011). Arginine methylation of 
histones is usually associated with transcriptional activation, providing a direct mechanism of 
epigenetic regulation by the modulation of the chromatin structure and accessibility to the 
transcriptional machinery. 
PRMTs can also methylate diverse non-histone proteins, including RNA-binding proteins 
(RBPs), transcriptional co-regulators and transcriptional elongation factors. RBPs represent 
 17 
major targets for PRMTs. Many proteins have been shown to be a substrate of PRMT1, which is 
the predominant type I PRMT in mammalian cells, accounting for 85% of cellular PRMT 
activity and influencing many cellular processes, such as transcription, RNA processing, RNA 
transport, translation, signal transduction, DNA repair, apoptosis. 
 
 
 
 
 
 
Fig. 2.1. Methylation of the arginine side chain by PRMTs. All PRMTs catalyze the formation of 
monomethyl-arginine (MMA) in an intermediate step. In a second step, type I PRMTs transfer a 
second methyl group to the same guanidino nitrogen resulting in an asymmetric dimethylarginine 
(aDMA), whereas type II PRMTs catalyze the formation of symmetric dimethylarginines (sDMA).  
(Picture taken by S. Pahlich et al. / Biochimica et Biophysica Acta 1764 (2006) 1890–1903). 
 
 
 
 
It has been demonstrated that arginine methylation can act as a maturation signal, because 
several RBPs (e.g., Sam68) are mislocalized after demethylation (Bedford, 2003; Lukong & 
Richard, 2004). Moreover, methylation status can alter the ability of RBPs to interact with their 
specific mRNA targets. The affinity of a particular RBP for its targets may be reduced, as the 
methyl group would prevent hydrogen bonding by steric hindrance. Alternatively, arginine 
methylation may promote RNA-protein interactions, as the arginine becomes more 
“hydrophobic” after methyl groups addition, increasing the stacking with the RNA bases. 
Despite phosphorylation or acetylation, methylation does not alter the charge of the proteins 
affected, thus resulting in a less pronounced effect on interactions mediated by arginine residues. 
It has been proposed that arginine methylation has a milder effect on proteins than other 
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posttranslational modifications, modulating certain processes rather than acting as an on/off 
switch (Pahlich et al., 2006).  
A number of molecules involved in the transcriptional machinery are also methylated by 
PRMTs. Two interesting PRMT substrates are the transcriptional elongation factor SPT5 and the 
activator of transcription STAT1: their methylation status affects respectively the association 
with RNA polymerase II (Kwak et al., 2003) and the DNA binding activity (Mowen et al., 
2001), confirming the important role of methylation in many cellular processes.  
 
 
 
Fig. 2.2. Overview of the human PRMT family. The numbers of amino acids indicates the 
length of each protein. PRMTs are divided into groups, depending on their catalytic 
activity. 
(Picture taken by S. Pahlich et al./Biochimica et Biophysica Acta 1764 (2006) 1890–
1903). 
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2.2 CARM1: structure and function 
Coactivator-associated arginine methyltransferase 1 (CARM1/PRMT4) is the first member of 
the arginine-specific protein methyltransferases (PMRTs) to be identified as a transcriptional 
regulator (Chen et al., 1999; McBride & Silver, 2001; Miranda et al., 2004). 
As a type I PRMT enzyme, CARM1 catalyzes the transfer of methyl groups from S-adenosyl-L-
methionine to the guanidine nitrogens of arginine, producing asymmetric dimethylated arginine 
as its final product. 
The human CARM1 gene is localized on chromosomal region 19p13.2. Three functional 
domains have been identified in the CARM1 protein: a central catalytic core and two additional 
domains at the N-terminal and C-terminal ends (Fig. 2.3). 
 
 
 
 
 
 
Fig. 2.3. CARM1 three functional domains. 
 
 
 
The catalytic core, a highly conserved domain composed of around 310 amino acids, contains 
both the S-adenosyl-methionine (AdoMet) and substrate binding domains. The enzyme-dead 
CARM1 knock-in mice displays defects similar to those seen in their knockout counterparts 
(Kim et al., 2010)supporting the idea that the enzymatic activity of CARM1 is essential for most 
CARM1-regulated processes. In contrast, the other two domains of CARM1 are dispensable for 
substrates methylation, but are required for the CARM1 coactivator function (Teyssier et al., 
2002). 
As generally said for PRMTs, a well-known substrate for CARM1 are histones (Di Lorenzo & 
Bedford, 2011): in response to hormone receptor activation, CARM1 methylates histone H3 on 
arginine residues number 2, 17, and 26. 
CARM1 can also methylate many other non-histone proteins. As a transcriptional co-activator, 
CARM1 is a key player in the formation of large complexes on gene promoters leading to 
chromatin remodeling and gene activation. Among the first co-activators shown to be 
methylated by CARM1, there are the histone acetyltransferase p300 and the CREB binding 
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protein (CBP). Methylation regulates the interaction of both these proteins with the DNA-
binding transcription factor CREB and, consequently, CREB ability to enhance transcription in 
response to cAMP (Chevillard-Briet et al., 2002). 
Finally, as said in general for PRMTs, many RNA-binding proteins (RBPs) such as the 
Polyadenylate-binding protein 1 (PABP1) (Yadav et al., 2003), the TAR DNA-binding protein-
43 (TDP43) (Carascossa, Dudek, Cenni, Briand, & Picard, 2010) and the ELAV protein 
members HuR and HuD have been shown to be methylated by CARM1 (Fujiwara et al., 2006; 
Hubers et al., 2011). The methylated state causes a structural conformational protein 
modification able to change the mRNA-stabilizing ability of such RNA-binding proteins and, 
thus, the half-life of their target mRNAs. 
 
 
 
 
2.3 ELAV protein methylation by CARM1 and neuronal differentiation 
The neuron-specific ELAV proteins (HuB, HuC, HuD) are RBPs that bind preferentially to AU-
rich elements (ARE) in the 3’ untranslated regions (3’UTR) of several mRNAs targets, 
increasing their stability and/or their translational efficiency (Pascale et al., 2008). ELAV 
proteins have been considered to be involved in the differentiation and/or maintenance of 
neurons, being most of their target genes involved in the cell cycle (for example p21, p27 and 
MYCN) and in neurogenesis (for example neurofilament-M, GAP-43 and tau). In agreement 
with this, it has been reported that overexpression of HuB and HuC in PC12 cells induces 
neuronal differentiation (Akamatsu et al., 1999), while overexpression of HuD accelerates 
neurite outgrowth in E19 rat cortical neurons, PC12 cells and retinoic acid-induced embryonic 
stem cells (Kasashima et al., 1999; Anderson et al., 2000; Mobarak et al., 2000; Anderson et al., 
2001). Moreover, several experimental evidences have showed that ELAV proteins are substrate 
for CARM1. The precise amino acid targeted by CARM1 for methylation has been mapped for 
HuR and HuD and corresponds to a highly conserved arginine residue within the so-called 
‘hinge region’ of ELAV family members (R217 for human HuR and R236 for human HuD), 
containing the cis elements responsible for ELAV nucleocytoplasmic shuttling (Fujiwara et al., 
2006; Good, 1997; H. Li et al., 2002; Okano & Darnell, 1997). 
Arginine methylation of ELAV proteins by CARM1 affects their neuroinductive potential 
(Fujiwara et al., 2006). In particular, it has been shown that CARM1 methylation of HuD at 
R236 negatively regulates its activity in PC12 cells and in the motor-neuron-derived MN-1 cell 
line model (Fujiwara et al., 2006; Hubers et al., 2011). As a consequence of this mechanism, the 
half-life of p21 mRNA (a HuD target known to be a key determinant in cell cycle arrest) 
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decreases, thus cells are supposed pushed to be maintained in an uncontrolled proliferation state, 
which prevents them to undergo neuronal differentiation (Fig. 2.4). 
 
 
 
 
 
 
 
 
 
Fig. 2.4. CARM1 possible mechanisms of action in driving proliferation or neurogenesis.  
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AIM OF THE PROJECT 
 
This thesis was directed to study neuroblastoma pathology and the project has been developed in 
collaboration with Associazione Italiana Per la Lotta al Neuroblastoma (Gaslini Hospital 
Genova, Italy).  
Neuroblastoma is a tumor showing a variable degree of cell undifferentiation, which is directly 
related with bad prognosis. This feature is most likely a consequence of a perturbation in the 
process of differentiation of neural crest stem cells during the development of the 
symphatoadrenal lineage of the nervous system.  
Therefore, molecular modulators that induce differentiation may be effective in the treatment of 
this malignancy. 
In this context, arginine methylation has been shown to play a pivotal role in cell development 
and differentiation, driving a number of cell lineages to acquire a finally correct phenotype. In 
particular, CARM1 (the coactivator-associated arginine methyltransferase 1) has been found to 
negatively regulate differentiation of PC12 pheochromocytoma cells by methylating the HuD 
RNA-binding protein, a known determinant of the neuronal phenotype. These data suggest that 
CARM1 inhibition could represent a possible therapeutic approach for neuroblastoma treatment.  
The work presented in this thesis aimed to investigate the role of CARM1 in the process of 
neuronal differentiation of the SK-N-BE(2) neuroblastoma cell line model, in order to clarify the 
effects of its methylation activity on neuroblastoma differentiation, and the possible involvement 
of the HuD RNA-binding protein in this process.  
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Chapter 3 
Materials and Methods 
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3.1 Materials 
In vitro models: Human Neuroblastoma cell lines 
17 parental Neuroblastoma cell lines were collected from different cell banks (ATCC, Virginia, 
U.S.A.; EACC, Salisbury, UK; Gaslini Hospital, Genova, Italy; DSMZ Human and Animal Cell 
Lines Database, Braunschweig - Germany).  
Human Caucasian Neuroblastoma cell lines SK-N-BE(2) was selected as the principal in vitro 
cellular model.  
SK-N-MC and SK-N-SH human neuroblastoma cell lines were cultured in DMEM (Sigma, Cat. 
N. D6546), supplemented by 10 % fetal bovine serum (FBS) (Lonza, Cat. N. DE14-801F), L-
Glutamine (2mM) (Lonza, Cat. N. BE17-605F) and 1mM sodium pyruvate (Lonza, Cat. N. 
BE13-115E). 
SK-N-AS and SK-N-DZ human neuroblastoma cell lines were cultured in DMEM (Lonza, Cat. 
N. BE12-614F), supplemented by 10 % fetal bovine serum (FBS) (Lonza, Cat. N. DE14-801F), 
L-Glutamine (2mM) (Lonza, Cat. N. BE17-605F) and 1% NEAA (Non Essential Amino Acids) 
(Lonza, Cat. N. BE13-114E).  
KELLY, NB-69, SIMA, MHH-NB-11, LAN-1, CHP-134 human neuroblastoma cell lines were 
cultured in RPMI-1640 (Lonza, Cat. N. BE12-167F) supplemented by 10 % FBS (Lonza, Cat. 
N. DE14-801F) and 2 mM L-Glutamine (Lonza, Cat. N. BE17-605F). 
 
 IMR-32 was cultured in EMEM (Sigma, Cat. N. M2279), 1% NEAA (Non Essential Amino 
Acids) (Lonza, Cat. N. BE13-114E), 10 % FBS (Lonza, Cat. N. DE14-801F), 2 mM L-
Glutamine (Lonza, Cat. N. BE17-605F) and 1mM sodium pyruvate (Lonza, Cat. N. BE13-
115E). 
CHP-212 and LAN-2 human neuroblastoma cell line were cultured in a mixture 1:1 EMEM 
(Sigma, Cat. N. M2279) + Ham’s F12 (Sigma, Cat. N. N4888), 10 % FBS (Lonza, Cat. N. 
DE14-801F) and 2 mM L-Glutamine (Lonza, Cat. N. BE17-605F).  
STA-NB-1, -7, -10 human neuroblastoma cell lines were cultured in RPMI-1640 with 
Ultraglutamin 1 (Lonza, Cat. N. BE12-702F/U1), 10% FBS (Lonza, Cat. N. DE14-801F), 2.5% 
Hepes Buffer solution 1M (Sigma, Cat. N. H3537) and 1% Sodium Pyruvate (Lonza, Cat. N. 
BE13-115E). 
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SK-N-BE(2) was cultured and maintained in 1:1 EMEM (Sigma, Cat. N. M2279), + Ham’s F12 
(Sigma, Cat. N. N4888), supplemented by 10 % fetal bovine serum (Lonza, Cat. N. DE14-
801F), L-Glutamine (2mM) Glutamine (Lonza, Cat. N. BE17-605F), Sodium Pyruvate  (1mM) 
(Lonza, Cat. N. BE13-115E), 1x Non-Essential Amino Acids (NEAA) (Lonza, Cat. N. BE13-
114E), Penicillin and Streptomycin (100 IU/ml). 
All the cells lines were kept at 37ºC in the presence of 5% CO2. When cells reached 60-70 % of 
confluence, they were passaged with 0.05% Trypsin in PBS, expanded and maintained in 
culture.  
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3.2 Methods  
3.2.1.   Stable Transfection Assay for silencing CARM1 gene 
For CARM1 knockdown, we used lentiviral transduction particles (MISSION Lentiviral 
Transduction Particles, Sigma-Aldrich). Briefly, 50.000 SK-N-BE(2) cells were seeded in a 6-
wells plate in complete medium prior to transduction, in order to reach a 60-80% confluence. 
After 24 hours, Polybrene was added to the cells to a final concentration of 8µg/ml. Lentiviral 
stock was slowly thawed on ice and the appropriate amount of viral particles was added at two 
different Multiplicity Of Infection (MOI): 2 and 10 MOI.  Plate was gently rocked to mix and 
incubated at 37ºC, 5% CO2. At day 3, viral particle-containing medium was removed and a fresh 
medium containing 0.5µg/ml of puromycin was replaced; the plate was incubated at 37ºC, 5% 
CO2. Fresh medium containing puromycin (0.5µg/ml) was replaced every 3-4 days to identify 
resistant colonies. Once reached 70% confluence, puromycin-resistant cells were expanded. 
Each pool of clones coming from different wells was assayed for CARM1 knockdown.  
 
3.2.2. Protein extraction  
 
For protein extraction, cells were suspended in RIPA buffer for mammalian cell lysis (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl 5M, IgePal CA-630 1%, EDTA 0.5M, Deoxicholate Sodium 
10%, SDS 10%) added with phosphatases (P-2850, P-5726, P-0044) and proteases inhibitors (P-
8340), provided by Sigma. 
Briefly, cells were collected from 10 cm diameter plates. Cells were first washed, scraped and 
collected on ice-cold phosphate-buffered saline (1X PBS). Cells were then centrifuged for 10 
min at 1.200 RPM and 4°C. Depending on the pellet size, cells were dissolved in 50-100 µl of 
RIPA buffer cleared by three rounds of freeze/thaw and then centrifuged for 40 min at 13.200 
RPM and 4°C. Supernatant was collected. Protein quantification was determined by Bradford 
assay according to the manufacturer’s protocol (Sigma B-6916). Absorbance was measured 
using an Infinite M200 plate reader (TECAN). Total protein extracts were collected and stored at 
-80°C until use. 
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3.2.3. Western Blot 
After quantification, an equal amount of proteins per sample was added with Protein Gel Sample 
Loading Buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% Glycerol, 1% Beta-Mercaptoethanol, 
12.5 mM EDTA, 0.02 % Bromophenol Blue) and heated at 99°C for 5 minutes. Proteins were 
then separated by 12% SDS-Page and transferred to PVDF membrane with a semi-dry blotting 
system (Trans-Blot® Transfer Medium, Bio-Rad Laboratories, Hercules, CA, USA). After 
saturation of the membrane with 5% BSA (Albumin from Bovine Serum, Sigma A3912) in 
TBS-Tween Buffer (Tris 20 mM, Tween 20, 0.2% NaCl 500, pH 7.5) for 1 hour at room 
temperature (RT), membrane was probed with different dilutions of antibodies (5% BSA in 
0.1% TBS-Tween) at RT for 1 hour or overnight at 4°C, depending on the antibody used. The 
following antibodies were tested: Hu PAN mouse monoclonal (1:250, ab14370, Abcam); 
CARM1 (1:2.000, IMG-90597-2, IMGENEX); beta-tubulin (1:1.000,sc-53140, Santa Cruz) or 
GAPDH (1:5.000, sc-32233 Santa Cruz) antibodies were used as endogenous control. The 
membrane was then washed three times with TBS-Tween before the incubation with secondary 
antibodies conjugated to horseradish peroxidase (Santa Cruz Biotechnology) at dilution 1:1.000 
to 1:5.000 in 5% BSA in TBS-Tween 0.1% for 1 hour at RT. The immunoreactions were 
visualized after addition of ECL-Plus Western blot detection system solutions (ECL Plus 
Western blotting Detection Reagents, GE-Healthcare Biosciences, Italy). Gels were scanned and 
lane densitometry analysis was performed using the Image J software. Molecular weight was 
estimated using Precision Plus Protein Standards Kaleidoscope (Bio-Rad).  
 
 
 
3.2.4. Operetta Analysis  
 
The Operetta™ (Perkin Elmer) is an automatic fluorescence microscope for High Content 
Screening applications. A High Content instrument is a platform comprising automated imaging 
instrumentation, image analysis software and high content informatics. This instrument allows to 
produce not only a morphological and well defined analysis of the cells, but also supports High 
Content Screening activities as it enables to quantify specific cellular phenotypes using different 
parameters.  
The analysis was performed in order to evaluate morphological changes in SK-N-BE(2) cell line 
with reduced CARM1 expression respect to the wild type control.  50.000 silenced and control 
SK-N-BE(2) cells were seeded in 24 well plates (Costar) and incubated at 37°C and 5% CO2.  
After 24 hours of incubation, cells were fixed with 4% Formaldehyde (Sigma) for 15 minutes at 
room temperature, then permeabilized with Triton X-100 (0.05% in PBS) for 10 minutes. Cells 
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were washed three times in PBS for 5 minutes, blocked in PBS-BSA 3% for 30 minutes and 
immunostained with beta III tubulin (1:700, ab18207, Abcam) in PBS-BSA 1% for one hour at 
37°C. After three washes in PBS for 10 minutes each, cells were incubated with a secondary 
conjugated goat anti-rabbit (1:500) (Alexa Fluor 488, A11070 Life Technologies) in PBS-BSA 
1% for one hour at room temperature in dark conditions. Then, cells were washed three times in 
PBS for 10 minutes each (in dark conditions). For DNA labeling, cells were incubated with a 
solution of 4µg/ml Hoechst 33342 (1:2.000 dilution, Life Technologies).  
Images have been acquired using an objective 20X LWD, using the following excitation (ex) 
and emission (em) filters: for Alexa 488: ex 480-490, em 500-550; for Hoechst 33342: ex 360-
400, em 410-480. 
For each condition, 4 replicate wells have been tested and 8 fields per well have been acquired, 
in order to get a significative number of objects for the subsequent analysis.  
 
Analysis was performed as follows: 
Nuclei Segmentation. The first step of an image analysis sequence is the identification of the 
objects of interest, in our case the nuclei (blue channel). Nuclei segmentation involves braking 
down the image into discrete objects (nuclei). The software (Harmony, PE) is able to assign a 
numeric parameter to every “object” (nucleus). Each selected object is shown as an overlay 
(image based information) and an entry in an object list (numerical data based information). This 
analysis is used to identify the cells and to define their number in every image acquired. Each 
image corresponds to one field of one well. Afterwards, the extension of the cytoplasm for each 
cell is detected basing on the green channel (beta III tubulin staining). Morphological properties 
of cells (cell dimensions and area) are then measured in order to allow the determination of sub 
populations of cells based on their properties. 
Subsequently, starting from the individual cell bodies, the extension of the cytoplasm for each 
cell is detected basing on the green channel (beta III tubulin staining) using the Find Neurites 
building block. Once the neurites have been identified, they can be processed and quantified 
depending on several morphological parameters, such as neurite length, number of roots, number 
of nodes, number of extremities, number of segments in the tree neurite, total length of all 
neurites in the tree. Neurite segments that are not connected to one of the cell’s neurite trees 
(“orphan neurites”) are listed in the “Neurite Segments” and they are not taken into account in 
any of the default parameters. In Fig. 3.1, a workflow of neurite detection is showed. 
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Fig.3.1. Workflow of neurite detection using Operetta high content screening detection. 
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3.2.5. Total RNA extraction 
Total RNA was extracted from SK-N-BE(2) cells using RNeasy Mini Kit (Qiagen) following 
manufacturer’s instructions. Briefly, biological samples were washed twice with PBS, scraped, 
collected and lysed with Buffer RLT, a highly denaturing guanidine-thiocyanate-containing 
buffer, which is able to inactivate RNases to ensure purification of intact RNA. An equal volume 
of 70% ethanol was then added to provide appropriate binding conditions and the samples were 
moved to the RNeasy spin columns (supplied by the kit) and centrifuged for 15 seconds at ≥ 
10.000 RPM. Spin columns contain a silica-based membrane that binds sample RNA and allows 
(with the speed of microspin technology) washing away contaminants. The bound RNA was 
washed with RW1 buffer and centrifuged at 10.000 RPM for 15 seconds, followed by two 
additional washes and centrifugation steps with RPE buffer. Finally, purified RNA was eluted 
off the column with RNase-free water. 
High-quality RNA was quantified to the NanoDrop Spectrophotometer ND-1000. Absorbance 
ratio at 260/280 nm and 260/230 nm was used to assess the purity of the samples. Agarose gel 
electrophoresis and staining with ethidium bromide indicated the high integrity of RNA samples. 
 
3.2.6. Microarray Analysis  
RNA Target Preparation/Agilent Microarray Analysis. 
Total RNA was extracted from SK-N-BE(2) cells silenced for CARM1 expression and the 
relative scramble control, as previously reported. The experiment was performed in biological 
triplicates plus one technical replicate as an internal control. RNA quality was assessed using the 
Agilent RNA 6000 Nano Kit (Agilent Technologies, Palo Alto, CA). One µg of total RNA was 
processed for the microarray hybridization with the Agilent Quick Amp Labeling Kit, according 
to the manufacturer's recommended protocols. Agilent's Quick Amp Labeling Kit uses cyanine 
3-labeled targets to measure gene expression in experimental and control samples. The method 
uses T7 RNA polymerase, which simultaneously amplifies target material and incorporates 
cyanine 3-labeled CTP. Figure 2 represents a scheme of amplified cRNA procedure. Briefly, 
after cDNA synthesis, with Agilent One-Color Spike-Mix and Cyanine 3-labeling incorporation 
amplified cRNA samples have been purified and quantified. Each sample underwent a quality 
control evaluation, including cRNA yield and specific activity, as follows: 
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Yield (µg of cRNA) = (Concentration of cRNA) x 30 µl (elution volume)  
                                                                 1000 
 
Specific activity (pmol Cy3 per µg cRNA) = Concentration of Cy3        x 1000 
                                                                        Concentration of cRNA 
 
 
 
Yield >1.65 µg and specific activity > 9 pmol Cy3 per µg cRNA are required for proceeding to 
the hybridization step.  
The resultant cyanine 3-labeled, linearly amplified cRNAs were fragmented and then hybridized 
on Agilent-014850 Whole Human Genome Microarray 4x44K G4112F, following the 
manifacturer’s protocol. Hybridized microarray slides were washed and scanned with the 
Agilent DNA Microarray Scanner G2505C at 5µm resolution with the manufacturer’s software 
(Agilent ScanControl 8.1.3) (Fig. 3.2). 
The scanned TIFF images were analyzed numerically using the Agilent Feature Extraction 
Software version 10.7.7.1, according to the Agilent standard protocol GE1_107_Sep09. The 
output of Feature Extraction was analyzed with the R software environment for statistical 
computing (http://r-project.org) and the Bioconductor library of biostatistical packages 
(http://bioconductor.org). 
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Fig.3.2. Scheme of amplified cRNA procedure. Generation of cRNA for a one-color 
microarray experiment (picture modified by One-Color Microarray-Based Gene Expression 
Analysis Protocol – Agilent). 
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Data pre-processing (background subtraction, signal normalization and data filtering) were 
performed with the Agi4x44PreProcess Bioconductor package (Fig. 3.3, 3.4, 3.5). Foreground 
signals (the gMeanSignal column from feature extraction) were corrected for background (the 
gBGMedianSignal column from feature extraction) with the “Normexp” method. Normalization 
between arrays was performed with the “quantile” method. Probes that didn’t reach quality 
criteria (signal within the dynamic range of the scanner, signal well above the local background, 
signal not saturated, signal with low pixel noise) in all the hybridizations were filtered out. In 
this way, from the 45.015 initial probes we obtained 26.833 probes, surpassing the quality tests. 
Summarization of replicated not control probes resulted in 25.050 final probes (Fig. 3.6). 
Differential expression between the control and the silenced samples was tested with the 
moderated t-test statistic implemented in the Limma package of Bioconductor. 1.738 probes 
with a Benjamini-Hochberg corrected p-value < 0.05 were selected as significantly differentially 
expressed. 541 probes, corresponding to 375 unique HGNC (HUGO Gene Nomenclature 
Committee) genes, have a positive log2 fold change (indicating up-regulation upon CARM1 
silencing), whereas 1.197 probes, corresponding to 880 unique HGNC genes, have a negative 
log2 fold change (indicating down-regulation upon CARM1 silencing).   
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Fig. 3.3. Box whisker plot of raw microarray signals from Feature extraction (expression signals are log2 
transformed).   
 
 
 
Fig. 3.4. Box whisker plot of normalized and background corrected microarray signals (expression signals 
are log2 transformed). Probes associated to genes and negative controls are displayed.  
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Fig. 3.5. Box whisker plot of microarray signals after data quality filtering (expression signals are log2 
transformed). 
 
 
 
Fig. 3.6. Distributions of microarray signals after data quality filtering and summarization (expression 
signals are log2 transformed). 
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DEGs Functional Analysis 
 
Functional analysis of the differentially expressed genes (DEGs) from high throughput data was 
performed using two alternative approaches: 
 
1) Enrichment analysis and enrichment clustering with DAVID (Database for Annotation, 
Visualization and Integrated Discovery) 
 
 
2) Gene Set Enrichment Analysis (GSEA):  
GSEA was performed on microarray data according to the procedure reported and software 
provided by Subramanian et al. (Subramanian, Tamayo, Mootha, Mukherjee, & Ebert, 2005) and 
the standalone Java implementation of the GSEA method from the Broad Institute website was 
used. All gene sets with more than 500 hits or less than 15 hits were automatically excluded, 
according to the default settings. The difference between signal-to-noise ratios was used as the 
association score. The number of phenotype permutations involved in the nominal p-value 
calculation was 1000. Gene sets were obtained from MSigDB (Molecular Signatures DataBase), 
containing almost 6769 gene sets, divided into five major collections: 
 c1: positional gene sets corresponding to each human chromosome and each cytogenetic 
band that has at least one gene. 
 c2: curated gene sets collected from various sources such as online pathway databases, 
publications in PubMed, and knowledge of domain experts. 
 c3: motif gene sets based on conserved cis-regulatory motifs from a comparative analysis 
of human, mouse, rat and dog genomes 
 c4: computational gene sets defined by expression neighborhoods centered on 380 cancer-
associated genes 
 c5: GO gene sets consisting of genes annotated by the same GO terms. 
 
For each analysis, we report the number of gene sets with a FDR (False Discovery Rate) <25%. 
Along with these gene sets with FDR <25%, we report the number of gene sets whose nominal 
p-values are <1%. 
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Microarray gene expression dataset analysis was previously also performed for 18 
neuroblastoma cell lines, of which 13 bearing MYCN amplification, and three primary cell lines 
(R1066, R1107, R113) isolated as spontaneously migrating neural crest cells from human fetal 
neural tubes, called human Neural Crest Cells (hNCC), in order to evaluate elav genes 
expression. Briefly, the gene expression dataset was analyzed by means of Agilent GeneSpring 
GX 10 software.  The first step of the analysis consisted in normalizing the input data: this was 
done by means of the 75
th
 percentile shift method, which computes the 75
th
 percentile of all data 
spots of a single array and then subtracts this value from these spots. No baseline to median 
transformation was applied.  Differentially expressed genes (DEGs) were then identified by 
means of the t-test method, again via GeneSpring, with a 0.05 threshold on p-value. 
 
3.2.7. Reverse transcription and quantitative PCR (qPCR)  
 
To remove trace amounts of genomic DNA, 1 µg of total RNA was treated with 1 unit of DNase 
I, RNase-free (Fermentas) according to the manufacturer’s instructions. Samples were then retro 
transcribed in a total volume of 20 µl by using RevertAid First Strand cDNA Synthesis Kit 
(Fermentas) and random primers, following the manufacturer's manual. 
The synthesized cDNAs were tenfold diluted, and 2 µl were used for qRT-PCR performed in a 
CFX96 real-time PCR detection system (Bio-Rad Laboratories) using KAPA PROBE FAST 
qPCR Master Mix (Resnova) in combination with selected TaqMan Gene Expression assays 
(Applied Biosystems). The following genes have been monitored: NEUROD2 (neurogenic 
differentiation factor 2), MAP1A (Microtubule-associated protein 1A), CDKN1A (cyclin-
dependent kinase inhibitor 1A), KIT (tyrosine-protein kinase Kit), BMP4 (Bone morphogenetic 
protein 4), INHBA (Inhibin, beta A) and PHOX2B (Paired-like homeobox 2b). 
qPCR was performed at 95°C for 3 minutes, followed by 40 cycles of 95°C for 3 sec and 60°C 
for 20 sec . Relative expression levels were normalized to the reference genes TBP (TATA-
binding protein) and HPRT1 (hypoxanthine guanine phosphoribosyl transferase). 
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3.2.8. Immunofluorescence Assay 
 
For HuD and CARM1 immunofluorescence assay, SK-N-BE(2) cells were plated in 24-well 
plates and grown up for one day; then, wells were rinsed with PBS and fixed for 15 minutes with 
paraformaldehyde 4% at 37ºC. After three washes with PBS (5 minutes each), permeabilization 
was carried out with 0.1% Triton X-100 in PBS for 10 minutes. Cells were then rinsed three 
times with PBS, blocked with 5% BSA and 0.05% Triton X-100 in PBS and incubated with 
different primary antibodies in blocking solution (dilution 1:200) overnight at 4ºC: HuD 
(dilution 1:200, sc-48421, Santa Cruz) and CARM1 (dilution 1:200, IMG-90597-2, IMGENEX). 
After overnight incubation the cells were rinsed trice with Triton 0.1% in PBS and incubated for 
1 hour at room temperature with Green Alexa Fluor 488 anti-rabbit (A11070 Life Technologies) 
and conjugate anti-mouse secondary Alexa 594 antibodies (A11020 Life Technologies). Nuclei 
were counterstained with DAPI (LifeTechnologies). Images were acquired with a 63X objective 
on a Zeiss Observer Z.1 microscope using the Axio Vision imaging software package (Zeiss). 
 
 
3.2.9. Plasmid construction and purification 
 
1 µg of total RNA extracted from SK-N-BE(2) cells was retrotranscribed and  the cDNA was 
used  for the cloning. Briefly, the human HuD cDNA was amplified with Pfu DNA polymerase 
(Stratagene) with the following primers containing Sgf I and Mlu I restriction sites, respectively: 
Forward 5’GCAGGCGATCGCCGAGCCTCAGGTGTCAAATGG 3’  (Sgf I) 
Reverse 5’ GACGACGCGTTCAGGACTTGTGGGCTTTGTTGG 3’  (Mlu I) 
 
The following touchdown PCR profile was used: 
 
1 cycle of 95°C for 3 min; 
2 cycles of 95°C for 10 sec, 62°C for 20 sec, 72°C for 4 min; 
2 cycles of 95°C for 10 sec, 60°C for 20 sec, 72°C for 4 min; 
2 cycles of 95°C for 10 sec, 58°C for 20 sec, 72°C for 4 min; 
15 cycles of 95°C for 10 sec, 56°C for 20 sec, 72°C for 4 min; 
1 cycle of 72°C for 10 minutes. 
 
The PCR product was digested with the same restriction enzymes and subcloned into the 
pCMV6-AN-His-HA plasmid (Origene) (Fig. 3.7), to render pHIS-HA-HuD.  
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After confirming the identity of the construct by sequencing, a large-scale purification of pHIS-
HA-HuD plasmid was conducted by ion-exchange chromatography with an Endofree plasmid 
Giga kit (QIAGEN, Valencia, CA), according to the manufacturer's instructions. Plasmid DNA 
was analyzed by agarose gel electrophoresis and quantified by spectrophotometry. The 260:280 
UV absorption ratios ranged from 1.8 to 2.0. Plasmids were stored in endotoxin-free water at 
−20°C until used. 
 
 
 
 
 
Fig. 3.7. Schematic representation of pCMV6-AN-His-HA plasmid, containing a CMV6 
promoter/enhancer for high-level expression in many mammalian cell lines, a multiple cloning (MCS) 
between SgfI and Mlu I restriction sites and a neomycin resistance gene for selection of stable cell lines 
using Geneticin. 
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3.2.10. Transient transfection of pHIS-HA-HuD plasmid and His-Tag isolation 
 
SK-N-BE(2) cells were seeded in 10 cm diameter plates and allowed to reach 70-80% of 
confluence. Transfections started 24 hours after seeding by using 18µl of TurboFectin 8.0 
(Origene) reagent and 6µg of the plasmid. Briefly, TurboFectin-containing media complex was 
prepared and plasmid DNA was added, mixed by gentle pipetting and incubated at room 
temperature for 30 minutes. The mixture was added drop wise to the cells and incubated for 48 
hours. Cells were lysed and quantified according to the method described previously. The lysate 
was then subjected to His-Tag isolation and pull-down by using Dynabeads® His-Tag 
(Invitrogen), optimized to bind histidine-tagged proteins. Briefly, 1 mg of protein lysate was 
resuspended in a total volume of 700µl of wash/binding buffer (PBS with 0.02% Tween-20) and 
incubated with 50µl of Dynabeads® His-Tag on a roller for 45 minutes at 4ºC. The beads were 
collected by using a magnet, washed four times with wash/binding buffer and incubated with 
100µl of elution buffer (PBS with 0.02% Tween-20 and Imidazol 300 mM) for 10 minutes at 
room temperature. Then, the beads were collected and the supernatant was resolved by 10% 
SDS-PAGE and probed with anti- His-probe antibody (sc-803, Santa Cruz Biotechnology) and 
CARM1 antibody (IMG-90597-2, IMGENEX). Both antibodies were used at 1:1000 dilutions. 
 
3.2.11. Transient Transfection Assay to over express HuD w/t and HuD mutants 
 
1µg of total RNA extracted from SK-N-BE(2) cells was retro-transcribed and  the cDNA was 
used  for the cloning. Briefly, a HA-tagged HuD sequence was amplified with Pfu DNA 
polymerase (Stratagene) by using the primer set: 5’-
GCACGGGATCCACTATGGAGTACCCATACGACGTACCAGATTACGCTGGAGCCTCA
GGTGTCAAATGG-3’ (forward) and 5’-GCAC 
GCTCGAGTCAGGACTTGTGGGCTTTGTTGG-3’ (reverse).  
The PCR product was digested with BamHI and XhoI restriction enzymes and cloned into the 
pcDNA 3.0 plasmid (Invitrogen Corporation, Carlsbad, CA), rendering the expression vector 
pHA-HuD w/t. 
The pHA-HuD vector was then used as template to generate, by PCR, two mutants of HuD, 
replacing the arginine at position 236 with a lysine (R236K) or a tryptophan (R236W), 
respectively. The primers containing the desired mutations (underlined) are listed as follows: 
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R248K: (F) 5′-CCACCAGGCTCAGAAGTTCAGGCTGGACA-3′ and 
(R) 5′-TGTCCAGCCTGAACTTCTGAGCCTGGTGG-3′;  
 
R248W: (F) 5′-CCACCAGGCTCAGTGGTTCAGGCTGGA-3′ and 
(R) 5′-TCCAGCCTGAACCACTGAGCCTGGTGG-3′.  
 
The DNA was then incubated with 20 U Dpn1 restriction enzyme for 1 hour at 37 °C before 
transformation into XL-1Blue cells. All plasmids were confirmed by sequencing. 
 
DNA transfection was performed as previously described. Cells were collected for protein 
extraction and quantification (see Western Blot protocol). Western Blot analysis was performed.  
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4.1 CARM1 silencing promotes morphological differentiation of MYCN-amplified 
neuroblastoma cells 
Neuronal cells are characterized by a high degree of differentiation, which is also continuously 
maintained by the influence of some RNA-binding proteins (RBPs) that drive these cells to a 
final, completely differentiated phenotype. For what we know, the role of RBPs is exerted 
during the whole flow of gene expression which ranges, after binding to the post-synthesis pre-
mRNAs, from polyadenylation to alternative splicing and nuclear export, to cytoplasmic 
localization, stability and translation of the bound mRNAs, by modulating their stability and 
their translational efficiency. In this contest, specific types of post-translational modifications of 
RNA binding proteins, such as methylation and demethylation, can be events able to influence 
RBP association to the target mRNAs, thus possibly modulating their activity on gene 
expression (Bedford, 2003; Lukong & Richard, 2004; Pahlich et al., 2006; Bedford & Clarke, 
2009). 
One of the most studied groups of RBPs involved in neuronal differentiation is the family of 
ELAV proteins: the human homologue HuR (a.k.a. ELAVL1) is ubiquitously expressed in all 
the cells, while HuB, HuC and HuD (a.k.a. ELAVL2, ELAVL3 and ELAVL4, respectively) are 
expressed only in neurons. However, the role played by these RBPs in the differentiation and 
maintenance of the neuronal phenotype, just well established in the past (see paragraph 2.3), 
suggests that they are not active in neuroblastoma cells. In this perspective, we know that HuR 
and HuD proteins are substrates for CARM1, which affects their neuroinductive potential 
(Fujiwara et al., 2006) through the methylation of the R217 for human HuR and the R236 for 
human HuD, as already discussed. Both arginines have been found to correspond to a highly 
conserved residue within the so-called ‘hinge region’ of ELAV family members, containing the 
cis elements responsible for ELAV nucleocytoplasmic shuttling capability. Taken together, these 
evidences are compatible with a possible negative influence of CARM1 in ELAV RBP activity 
and, as a consequence, a loss of differentiation phenotype in neuroblastoma cells. Thus, the 
purpose of this thesis was to demonstrate the role of CARM1 in counteracting the mechanisms 
underlying differentiation in a neuroblastoma cell line model, SK-N-BE(2) and, if possible, 
trying to demonstrate the direct influence of CARM1 methylation upon ELAV proteins.  
In order to do that, CARM1 activity has been disrupted by RNA silencing with the use of a 
lentiviral vector. SK-N-BE(2) cells have been infected with a lentiviral vector bearing an shRNA 
against CARM1 with two different virus concentrations: 2 and 10 MOI (multiplicity of 
infection). A suitable control was the same cell line infected with a lentiviral vector bearing a 
scramble sequence. We performed a quantitative RT-PCR analysis in order to evaluate CARM1 
knock down at transcript levels. As clearly shown in Fig. 4.1A, these constructs led to a 80% of 
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decrease in CARM1 expression levels, compared to the control cells. Reduction in CARM1 
protein level (figure 4.1 A and B) was also confirmed by western blot analysis in both 
multiplicities of infection. In SK-N-BE(2) cells silenced for CARM1, CARM1 protein levels 
were almost completely knocked down. 
 
 
 
 
 
Fig. 4.1. Stable silencing of CARM1 expression in SK-N-BE(2) cell line. (A)Total proteins were extracted 
from scramble SK-N-BE(2) and shCARM1 SK-N-BE(2) cells infected with two different viral titres (2 
MOI and 10MOI) and blotted with an antibody against CARM1. Samples were normalized to the 
endogenous control GAPDH. (B) Percentage of CARM1 protein expression level after CARM1 silencing, 
for both the multiplicities of infection.  
B 
A 
SKNBE2_ctrl 2MOI 10MOI 
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To check if CARM1 activity can modulate SK-N-BE(2) differentiation, morphological changes 
in shCARM1 SKNBE(2) cells were evaluated by means of an high throughput approach, an 
automatic fluorescence microscope system for high content screening: the Operetta™ (Perkin 
Elmer) system (see Materials and Methods for details). In brief, Operetta is a new fluorescence 
microscopy able to measure and analyze specific parameters on a cell, in a multi-well plate 
format. This allows considering a high number of objects to be investigated in every analysis 
performed. In order to evaluate neurite outgrowth in SK-N-BE(2) cells silenced for CARM1 
with respect to the scramble-infected control, we performed an immunofluorescence assay using 
beta III tubulin antibody, a commonly used marker for neuronal differentiation. Then, we 
compared several parameters related to neurite outgrowth. The Operetta software is able to 
analyze and measure the fluorescently labeled neurites with respect to their total length, 
maximum length, number of roots, number of extremities and number of nodes. A special 
algorithm uses Hoechst staining to detect the nuclei and create cell body boundaries around 
them. The second fluorescent channel (green, detecting beta III tubulin) is used by the software 
to define the neurite network. This software can be set in order to remove broken neurites or 
neurites that do not “belong” to a cell’s neurite tree (they are called “orphan neurites” and listed 
in the Neurite Segments). After the detection of the neurites, generated fluorescent images allow 
to “read” and understand the outcome of the analyzed parameters. Three morphological 
parameters related to the process of differentiation have been evaluated for each cell considered: 
the maximum neurite length (a parameter referred to the longest neurite present in every cell), 
the total length of neurites (a parameter referred to the sum of the length of each neurite per 
cell), and the number of roots for each cell (a parameter increased in neuroblasts undergoing 
differentiation). The measure was done in more than one thousand randomly chosen cells.  
As clearly shown in the histograms of Fig. 4.2, the SK-N-BE(2) cell line population with a 
silenced CARM1 expression shows a moderate increase in all the parameters analyzed. Indeed, 
being equal the number of cells (objects) considered (scramble=1601±122; 
shCARM1=1395±163), the maximum length of neurites, the total length of neurites and the 
number of roots per cell are significantly higher in CARM1 silenced compared to the scramble 
control cells (respectively mean per well scramble=13,95±0,72 px while shCARM1=22,27±0,29 
px; scramble=19,31±1,14 px while shCARM1=33,4±1,99 px; scramble=0,49±0,03 px while 
shCARM1=0,67±0,01 px), possibly sustaining our hypothesis of a CARM1 involvement in 
maintaining an undifferentiated phenotype in neuroblastoma cells. 
Indeed, even if it is possible to appreciate an increase in neuronal-like phenotype for SK-N-
BE(2) cells with reduced CARM1 expression (figure 4.2 A, right), a sub-population of cells, 
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showing a “flattened”, non neural-like morphology, is still present, probably because of a partial 
inefficiency of CARM1 silencing following lentiviral vector infection. 
 
 
 
 
Fig. 4.2. High-content analysis of scramble SK-N-BE(2) compared to shCARM1 SK-N-
BE(2). (A) Immunofluorescent image showing morphologic differences between SK-N-
BE(2) scramble and SK-N-BE(2) with reduced CARM1 expression. (B) Number of 
analyzed objects. (C-E) Neurite outgrowth readouts considered. Data represent the means 
+/- standard errors of the means from four replicates. 
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4.2 Transcriptome profile of CARM1-silenced neuroblastoma cells  
The flow of genetic information can be modulated at different levels, from transcription to 
translation and post-translational events. These modulating events are fundamental in driving all 
major cellular programs, including differentiation and the establishment of the phenotype. 
During the last decade, the study of dynamics of gene expression regulation has been possible 
due to the use of high-throughput screening techniques, which allow going deep in details of the 
molecular events involved. For this reason, in order to study neuronal differentiation more 
carefully than with morphological examination and with the use of surrogate markers of 
phenotypic features, we look in an unbiased way to the whole set of gene expression changes 
taking place in neuroblastoma cells with reduced CARM1 expression. We subjected scramble 
and shCARM1 SK-N-BE(2) cells to transcriptome profiling by microarray analysis. Total RNA 
from SK-N-BE(2) cells silenced for CARM1 expression and the relative scramble controls were 
hybridized on Agilent microarrays (for details on the procedure, see Materials and Methods 
paragraph 3.2.6). Raw data from scanned images were analyzed through the R software 
environment for statistical computing. Data were processed for background subtraction and data 
filtering, obtaining 26.833 probes that surpassed the quality tests. Normalization between arrays 
was performed with the “quantile” method. The moderated statistic t-test implemented in the 
Limma package of Bioconductor was used to measure the statistical significance of the 
differential expression between the control and the silenced samples and a Benjamini-Hochberg 
corrected p-value < 0.05 was used to select for significantly differentially expressed genes. 541 
probes, corresponding to 375 unique HGNC (the HUGO Gene Nomenclature Committee) 
genes, have a positive log2 fold change (indicating up-regulation upon CARM1 silencing), 
whereas 1.197 probes, corresponding to 880 unique HGNC genes, have a negative log2 fold 
change (indicating down-regulation upon CARM1 silencing (Fig. 4.3 and Fig. 4.4, 
respectively). A hierarchical clustering of samples was performed with the signals of 
differentially expressed genes (DEGs) and the results are visualized in Figure 4.5: “C” represent 
control samples, whereas “S” represent SK-N-BE(2) samples silenced for CARM1 expression.  
As evidenced in the resulting tree, the two experimental conditions are well distinguishable. 
Each row represents a gene, but DEGs were too numerous to be explicitly labelled in the figure. 
The heatmap shows that, for SK-N-BE(2) cells silenced for CARM1 expression, the number of 
significantly down-regulated genes is higher than the number of up-regulated genes. This result 
could suggest  for CARM1 a prevalent activating role in the modulation of gene expression. 
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Fig. 4.3. Number of up-regulated and down-regulated HGNC genes after CARM1 
silencing in SK-N-BE(2) cells. 
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Fig. 4.4. Histogram with the distribution of the log2 fold change (FC) values of up-regulated (dark grey) 
and down-regulated (light grey) HGNC genes. 
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Fig. 4.5. Heatmap of microarray signals of differentially expressed genes, with clustering of samples. 
In the hierarchical clustering tree,all biological replicates of the shCARM1 samples are well divided 
from the biological replicates of the scrambled control samples. 
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Since our interest was directed to define the modulation of gene expression  of neuroblastoma 
cells after CARM1 silencing, we investigated the presence of ontological enrichments of 
differentially expressed genes by the use of DAVID, the Database for Annotation, Visualization 
and Integrated Discovery. Basically, we submitted our gene list to the database, obtaining the 
identification of ontological terms significantly overrepresented (using the Fisher test). This 
approach suggests possible mechanisms of regulation and/or functional pathways that are 
primarily activated or suppressed as a response to CARM1 silencing. The Gene Ontology, 
structured in three different domains, was used to describe genes in terms of their biological 
processes (BP), cellular components (CC) and molecular functions (MF). The enrichment was 
produced separately for up-regulated genes (DAVID UP ENRICHMENT LIST) and down-
regulated genes (DAVID DOWN ENRICHMENT LIST). We selected, as significantly 
enriched, GO terms with a Benjamini-Hochberg corrected p-value <0.05 (figure 4.5). Among 
the overrepresented GO terms we found important terms referred to neuronal development, such 
as “neuron differentiation”, “chordate embryonic development” and “neural crest stem cell” 
(figure 4.6). 
The enriched terms “neuron differentiation” (figure 4.7) and “chordate embryonic development” 
(figure 4.8), including 48 and 43 DEGs respectively, underline a prevalent role of CARM1 in 
modulating the embryonic development, as previously said. Some of these genes are of interest 
for the analysis of microarray results, such as Contactin-2 (Cntn2, 2.17 log2 FC), a neuronal 
membrane protein playing a role as adhesion molecule and in the formation of axon connections 
in the developing nervous system, and Netrin-4 (Ntn4, 1.85 log2 FC), which may play an 
important role in neural, kidney and vascular development. As kidney represents one of the 
primary sites of neuroblastoma onset, Netrin-4 upregulation could be suggestive of the possible 
induction of undifferentiated cells (in this case, our model SK-N-BE(2) cells after CARM1 
silencing) to neuronal features. Of interest, RXRA gene (0.70 log2 FC) encoding for the retinoid 
X receptor alpha, is a nuclear receptor able to mediate biological effects of retinoids. Being 
retinoids fundamental in nervous system development and in the induction of neuronal 
differentiation and growth arrest of malignant neuroblastoma in vitro (V B Christie et al., 2008; 
Melino, Thiele, Knight, & Piacentini, 1997, as previously reported, see chapter 1.4), these results 
could also be consistent with the hypothesis that SK-N-BE(2) cells, silenced for CARM1, 
acquire neuronal traits. However, despite the upregulation of important genes representative of 
neuronal features, it is clearly evident (figure 4.7) that the number of up-regulated genes is 
consistently lower than the number of down-regulated ones, being only 11 the number of up-
regulated genes in the list of significantly DEGs associated to “neuron differentiation” terms 
respect to 37 down-regulated genes (see figure 4.7). The same consideration can be proposed for 
the GO enriched term “chordate embryonic development”. Indeed, as clearly visible in figure 
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4.8, the modulation of the expression of genes involved in developmental processes after 
CARM1 silencing is evident, although not entirely directed to the acquisition of neuronal traits. 
Among this group, many genes are transcription factors involved in cellular development and 
differentiation, such as TWIST1 (-2.03 log2 FC), a basic-helix-loop-helix transcription factor 
shown to be implicated in cellular lineage determination and differentiation; Gli2 (0.7 log2 FC), 
a transcription factor mediating Sonic Hedgehog (Shh) signalling, one of the most important 
pathways involved in embryonic development; Tulp3 (0.73 log2 FC), a transcription factor 
playing an essential role in maintenance and function of neuronal cells during development and 
post-differentiation (Ikeda et al., 2001; Ikeda, Nishina, & Naggert, 2002); Hand2 (-0.88 log2 
FC), a basic helix-loop-helix transcription factor which  has been demonstrated to be essential 
for the proliferation of immature sympathetic neurons in vivo (Hendershot et al., 2009; Schmidt 
et al., 2010) and resulting to be down-regulated in SK-N-BE(2) silenced for CARM1. 
Concerning Hox genes (classified in four clusters: A, B, C, D), this group of related genes are 
involved in controlling the anterior-posterior axis development during embryogenesis. Actually, 
9 genes have been found to belong to the HoxD family: HoxD1, HoxD3, HoxD4, HoxD8-13. A 
recently published paper (Zha et al., 2012) has shown an induction of  several HoxD genes by 
retinoic acid (RA), thus enhancing cell cycle arrest and neuronal differentiation of SK-N-BE(2)-
C cell line, a clone of SK-N-BE(2) neuroblastoma cell line. Nonetheless, the authors show that 
in absence of RA-induction, the effect of HOXD8, HOXD9, HOXD10 and HOXD12 genes in 
promoting neuronal differentiation is partially reduced, whereas HOXD1 seems to have no 
phenotypic effect on differentiation and HOXD3 seems to be able to induce cell cycle arrest and 
morphologic differentiation but fails the up-regulation of neurofilament medium, a well-known 
neuronal marker involved in maintaining neuronal axonal structure. Our microarray profiling 
shows a down-regulation of three genes belonging to the HoxD family in SK-N-BE(2) cells with 
reduced CARM1 expression (HoxD1, -1.3 log2 FC; HoxD3, -2.01 log2 FC; HoxD9, -1.28 log2 
FC), although, at least for HoxD1, down-regulation probably might not have a dramatic impact 
on embryonic development. Despite considering these evidences, there are only 15 up-regulated 
DEGs associated to the “chordate embryonic development” terms respect to a total number of 28 
down-regulated genes (see figure 4.8), again underlying the possible role of CARM1 in 
modulating gene expression in a direction that is not  necessarily neuronal-like . 
Other evidences about the possible effects of CARM1 depletion in conditioning neuronal 
differentiation are supported by the presence of known specific genes associated to “neural crest 
cell development” term, such as for example Neuregulin1 (Nrg1, 1.63 log2 FC), a protein related 
to the EGF family, which has been shown to induce and preserve neuronal survival (Croslan et 
al., 2009). Moreover, the anti-proliferative Phox2B, another indicator of neuronal cell 
differentiation and a genetic marker for neuroblastoma predisposition, has been shown to be 
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upregulated upon CARM1 silencing (2.9 log2 FC). Finally, albeit not belonging to the GO over-
represented terms, two genes can be considered of interest for our analysis: cdkn1a (a.k.a. p21), 
a key gene promoting neuroblast cell cycle exit during neuronal differentiation (see paragraph 
2.3 and Buttitta & Edgar, 2007; Dobashi, Kudoh, Matsumine, Toyoshima, & Akiyama, 1995; 
Galderisi, Jori, & Giordano, 2003; Joseph, Orlian, & Furneaux, 1998; Myster & Duronio, 2000; 
Yano, Okano, & Okano, 2005), is upregulated (1.6 log2 FC) in SK-N-BE(2) in shCARM1 cells; 
moreover, nestin, a known marker of staminality, is downregulated (-1.4 log2 FC) in SK-N-
BE(2) cells silenced for CARM1 expression. This result allows us only to speculate that 
CARM1 could be responsible for favouring the loss of stemness properties in neuroblastoma 
cells.  
In conclusion, the whole set of gene expression changes taking place in neuroblastoma cells with 
reduced CARM1 expression, after normalization and the Benjamini-Hochberg correction for the 
selection of significantly differentially expressed genes, resulted in 375 genes with a positive 
log2 fold change (indicating an up-regulation following CARM1 silencing) and 880 genes with a 
negative log2 fold change (indicating a down-regulation after CARM1 knock-down). Among 
these, DAVID analysis resulted in interesting GO enriched terms (such as “neuron 
differentiation”, “chordate embryonic development” and “neural crest cell development”) which 
underlined the role of CARM1 in gene expression modulation. However, as clearly visible in the 
reuslts reported in figure 4.7 and 4.8, the modulation seems to be directed to a non neuronal-like 
condition, allowing us to speculate that CARM1 silencing could just induce a loss of stemness-
like shape in neuroblastoma cells. Therefore, these evidences prompt us to conclude that 
microarray screening, directed to define the modulation of gene expression in our neuroblastoma 
cell line model after CARM1 silencing, do not support the hypothesis of a neuronal 
differentiation induced after CARM1 silencing but, on the contrary, CARM1 depletion seems to 
selectively “turning off” their own genes that are typical of neuronal differentiation. 
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Fig. 4.6. Heatmap of ontological enrichment. Cells are coloured according to the –log10 enrichment p-
value, as calculated in the list of up-regulated DEGs (first column), the list of down-regulated DEGs 
(second column) and the list of both up-regulated and down-regulated DEGs (third column). Significant 
enrichments (p-value < 0.05) are colored in shades of green. 
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Gene Symbol log2 FC 
CNTN2 2,17 
NTN4 1,85 
VEGFA 1,62 
ID3 1,45 
TULP3 0,72 
GLI2 0,72 
RXRA 0,70 
DAPK3 0,67 
PTPRM 0,63 
NEDD4 0,62 
BHLHE22 0,46 
B3GNT2 -0,49 
C17orf28 -0,56 
DFNA5 -0,57 
HOXC10 -0,67 
CNTN4 -0,68 
DOCK7 -0,78 
DSCAML1 -0,81 
IRX5 -0,82 
GAS7 -0,84 
EPHB2 -0,89 
IGF1R -0,92 
DCLK1 -0,94 
NTNG1 -1,00 
PTEN -1,06 
STMN2 -1,12 
SLIT3 -1,19 
EDN3 -1,26 
HOXD9 -1,28 
ROBO2 -1,29 
RORB -1,31 
CDKN1C -1,33 
MYH10 -1,36 
UNC5C -1,45 
NEFL -1,46 
SMO -1,51 
FEZ1 -1,52 
BMPR1B -1,53 
GFRA3 -1,66 
RORA -1,71 
NRP2 -1,79 
OPCML -1,79 
CXCR4 -1,83 
BCL2 -1,85 
ISL1 -2,05 
PTPRR -2,17 
SLIT1 -2,33 
SLITRK6 -2,35 
 
Fig. 4.7. List of significantly differentially expressed genes (DEGs) associated to “neuron differentiation” 
terms. 
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Fig. 4.8. Heatmap representing differentially expressed genes (DEGs) associated to the “chordate 
embryonic development” terms.  
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4.3 CARM1-silenced neuroblastoma cells show increased neuronal lineage markers and 
decreased neural stem cell markers 
In parallel, since the microarray profile showed a great variability of gene expression in SK-N-
BE(2) cells with reduced CARM1 expression, we decided to perform a qRT-PCR to evaluate, on 
the samples that we used for microarray analysis, either CARM1 expression and other genes 
involved in neuron differentiation and staminality processes, in order to test the potential shift of 
phenotypic features in SK-N-BE(2) cells subjected to CARM1 down regulation. Samples named 
“C” are representative of biological replicates of scramble SK-N-BE(2) cells control, whereas 
samples named “S” indicate SK-N-BE(2) replicates knocked-down for CARM1 expression. As 
clearly visible in figure 4.9, scramble controls (samples “C”) have higher levels of CARM1 with 
respect to the silenced cells (samples “S”). However, as previously observed (see paragraph 4.1), 
we did not obtain a 100% CARM1 silencing. We selected few genes known to be markers of 
neuronal differentiation (NeuroD2, MAP1A, PHOX2B and INHBA) and two genes involved in 
the maintenance of neural stem cell conditions (c-KIT and BMP4) and we subjected them to 
quantitative RT-PCR in RNA biological replicates of SK-N-BE(2) cells both silenced for 
CARM1 and infected with scramble shRNA. NeuroD2 (neurogenic differentiation factor 2) is a 
transcription factor implicated in neuronal differentiation (Franklin, Kao, Tapscott, & Unis, 
2001; C. Ravanpay, Stacey J. Hansen, 2011; Sugimoto, Furuno, & Nakanishi, 2009), including 
evidences of a direct involvement in blocking neuroblastoma growth and progression both in 
human and mouse neuroblastoma cell lines (Messmer, Shen, Remington, & Fishman, 2012; Mie, 
Endoh, Yanagida, Kobatake, & Aizawa, 2003; Noda, Kawamura, Funabashi, Mie, & Kobatake, 
2006), whereas MAP1A (microtubule-associated protein 1A) is fundamental in maintaining the 
cellular cytoskeletal architecture in differentiated cells and seems to be involved in neurogenesis 
and in playing a pivotal role in early events of spinal cord development (Avila, Domínguez, & 
Díaz-Nido, 1994; Dorman, 1990). After stable CARM1 knockdown, we found an increase in 
NeuroD2 and MAP1A mRNA levels with respect to the scramble control, these results 
suggesting that CARM1 silencing could play an important role in the process of differentiation 
in neuroblastoma cells. Assessment of the stemness state in the two populations of cells was 
employed, as said, by the stemness-related c-KIT and BMP4 markers. c-KIT is a tyrosine kinase 
receptor for SCF (stem cell factor) that plays an essential role in the regulation of cell survival, 
proliferation and maintenance of the stem cell state (Ray, Krishnamoorthy, & Ray, 2008; Sun, 
Lee, & Fine, 2004). Previous results have demonstrated that c-KIT phosphorylation due to 
imatinib mesylate (a selective inhibitor of several structurally related receptor tyrosine kinases) 
is able to arrest growth of neuroblastoma cell lines (Vitali et al., 2003). c-KIT and SCF 
expression have been prevalently found in tumors harboring genomic amplification of MYCN, 
of which our cell line model SK-N-BE(2) cells are an example. We therefore tested c-KIT 
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mRNA level changes in the two cellular conditions. As shown in Fig. 4.9, a decrease of c-KIT is 
clearly visible in SK-N-BE(2) cells silenced for CARM1, confirming the loss of stemness 
potential. We also checked the expression levels of BMP4 (bone morphogenetic protein 4), a 
member of the transforming growth factor-beta superfamily. These molecules are expressed at 
the early steps of embryo development and they act in establishing the dorsal-ventral axis of the 
neural tube (Cheung et al., 2005; Crane & Trainor, 2006; Gammill & Bronner-Fraser, 2003; 
Huang & Saint-Jeannet, 2004; Knecht & Bronner-Fraser, 2002; Meulemans & Bronner-Fraser, 
2004; Meulemans & Bronner-fraser, 2005; Villanueva, Glavic, Ruiz, & Mayor, 2002). As 
anticipated, BMP4 levels are drastically decreased in SK-N-BE(2) cell silenced for CARM1, 
confirming a reduction of stem cell features after CARM1 silencing (Figure 4.9). 
Furthermore, we tested the mRNA levels of p21 (also known as CDKN1A), a key gene 
promoting neuroblast cell cycle exit during neuronal differentiation (Buttitta & Edgar, 2007; 
Dobashi, Kudoh, Matsumine, Toyoshima, & Akiyama, 1995; Galderisi, Jori, & Giordano, 2003; 
Joseph, Orlian, & Furneaux, 1998; Myster & Duronio, 2000; Yano, Okano, & Okano, 2005). 
Several publications showed an up-regulation of p21 during neuronal differentiation both at 
translational (Dobashi et al., 1995; Erhardt & Pittman, 1998) and post-translational levels 
(Gorospe, Wang, & Holbrook, 1998). Interestingly (see later), p21 mRNA is also known to be a 
target of HuD (Joseph, Orlian, & Furneaux, 1998; Fujiwara et al., 2006; Hubers, Valderrama-
carvajal, Laframboise, & Timbers, 2010). Confirming our assumptions and the microarray data, 
p21 has been found to be elevated in SK-N-BE(2) silenced for CARM1 with respect to the 
scramble control. As p21 is involved in driving the cell to exit cell cycle and starting 
differentiation processes, an increase in p21 mRNA levels after CARM1 knockdown further 
corroborates our hypothesis of a possible role of CARM1 in maintaining the cells in an 
undifferentiated condition. 
Finally, we checked two more genes that have been shown to correlate with reduced 
proliferation and a promotion of neuronal differentiation in neuroblasts: PHOX2B and Inhibin 
beta A (INHBA). PHOX2B is a transcription factor exclusively expressed in the nervous system 
(particularly in neurons controlling cardiovascular, digestive and respiratory systems) and 
involved in neuronal cell cycle exit and identity of neuronal cells (Reiff et al., 2010; Dubreuil et 
al., 2000). PHOX2B has been demonstrated to be mutated in rare familial cases of 
neuroblastoma (Parodi et al., 2012; Kamijo & Nakagawara, 2012; Normand, Michon, Janoueix-
Lerosey, Delattre, & Schleiermacher, 2011), thus suggesting its role as indicator of prognosis in 
neuroblastoma disease. INHBA is constituted by two distinct, but closely related, glycoproteins: 
Activin and Inhibin, with opposing biological effects. They both belong to the superfamily of 
TGF-beta proteins. As Inhibin down regulates FSH synthesis and inhibits FSH secretion, Activin 
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enhances FSH biosynthesis and secretion, but, most importantly, together they are able to exert 
other cellular functions, such as cellular regulation, differentiation and apoptosis. Activin A and 
the Inhibin beta A homodimer plays an essential role in angiogenesis inhibition, which is down 
regulated by N-Myc amplification in neuroblastoma tumors (Schramm et al., 2005). Therefore, 
INHBA expression is currently used as a molecular marker for neuroblastoma differentiation. In 
agreement with these remarks, CARM1 silenced cells showed the up-regulation of these genes 
(Fig. 4.9), thus underlying the ability of CARM1 to inhibit the expression of key neuronal 
markers in SK-N-BE(2) cells. Together with the shift towards the neuronal-like phenotype 
evidenced by immunofluorescence after CARM1 silencing (see chapter 4.1), these results would 
prompt us to conclude that CARM1 silencing, in the MYCN-amplified SK-N-BE(2) 
neuroblastoma cells, promotes an up regulation of key transcripts responsible for  neuronal 
differentiation (INHBA, MAP1 and p21) and a down regulation of key stemness transcripts 
(BMP4 and c-KIT). This evidence only suggests the possibility of a transition from stemness to 
a differentiation program in cells of neuroblastoma lacking CARM1, differentiation that is not 
necessarily neuron-like. 
 
 
 
Figure 4.9. Quantitative RT-PCR analysis on selected genes for microarray validation. C1, C2 and C3 
represent the three biological replicates of SK-N-BE(2) cells wild type for CARM1 expression, whereas 
S1, S2 and S3 represent SK-N-BE(2) replicates with CARM1 knockdown. qPCR values are mean ± SEM 
of three independent experiments. 
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In order to go further, we decided to compare our microarray experiment with previous 
published experimental evidences in which CARM1 has been silenced. In one recently published 
paper, Wu and colleagues (Wu et al., 2009) silenced CARM1 expression in a embryonic stem 
(ES) cell mouse model, observing a suppression of the most important genes involved in 
maintaining pluripotency and an increase in genes  related to “development” and 
“differentiation”. Making a comparison between our and this dataset by orthologs DEGs, we 
found 26 commonly up-regulated genes, 27 commonly down-regulated genes and 42 discordant 
genes (figure 4.10 and supplementary data). Among the 28 commonly up-regulated genes, we 
found cdkn1a (a.k.a. p21; Wu log2 FC: 1.29, our log2 FC: 1.61), which role in driving cell cycle 
progression has been discussed (see paragraph 2.3 and 4.2); Id3 (Wu log2 FC: 0.89; our log2 
FC: 1.45), a negative transcriptional modulators involved at different steps in gene expression 
modulation (Ellmeier & Weith, 1995); NDRG1 (Wu log2 FC: 1.29; our log2 FC: 1.61), a 
component of the alpha/beta hydrolase family, which has a fundamental role for p53-mediated 
caspase activation and apoptosis (Jiang, Shen, Ye, Yang, & Wang, 2010); DLX3, a known 
transcriptional regulator of osteoblast differentiation (Hassan et al., 2004; Wu log2 FC: 1.0; our 
log2 FC: 1.49); ARID3A, a DNA-binding protein involved in normal embryogenesis (An et al., 
2010; Webb et al., 2011; Wu log2 FC: 1.17; our log2 FC: 0.84).  
Among the 28 commonly down-regulated genes, we found c-Kit (Wu log2 FC: -1.06; our log2 
FC: -1.99), which plays an essential role in the maintenance of the stem cell state, as previously 
discussed (see chapter 4.2); CDCA7L (cell division cycle associated 7-like, Wu log2 FC: -1.03; 
our log2 FC: -1.14), a protein associated to cell cycle regulation; STMN2 (Stathmin-like 2, Wu 
log2 FC: -1.06; our log2 FC: -1.12), a silencer element playing a regulatory role in neuronal 
growth. Discrepancies in 42 genes might be due to the different model analysed (embryonic 
stem (ES) cell mouse model versus human neuroblastoma cell model), to the comparison 
between a healthy cell line (mouse model) and a tumorigenic cell line (neuroblastoma model), or 
because of differences in CARM1 gene silencing among the experiments. Nonetheless, the 
elevated number of DEGs matching between microarray analysis performed by Wu and our 
microarray results prompt us to sustain the hypothesis that CARM1 down-regulation is a 
possible event in driving the cells to differentiation. 
 
 
 
 
 
 
 
 61 
 
 
 
 
 
 
 
 
Fig. 4.10. Comparison between Wu’s DEGs in the B-35 ES cell mouse model and DEGs obtained by our 
microarray profiling. 
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We also decided to focus our attention on pathways associated with CARM1 silencing using the 
gene set enrichment analysis (GSEA), a widely used statistical analysis for the identification of 
enriched biological functional categories in sets of pre-ranked differentially expressed genes 
(Ma’ayan, 2011; Subramanian et al., 2005). We subjected the list of DEGs to the Molecular 
Signatures Database (MSigDB), a collection of annotated gene sets associated with the GSEA 
software. As previously detailed in Materials and Methods (Chapter 3.2.6), for each analysis we 
used as significance threshold a false discovery rate (FDR) < 25%. By this analysis, we obtained 
a list of 19 gene sets with significant enrichment of DEGs found to be up regulated in our 
analysis (positive phenotype) and 33 gene sets with a significant enrichment of DEGs found to 
be down regulated (negative phenotype) in our analysis. Three of these gene sets are potentially 
related to neuroblastoma pathology. The gene set ezh2_targets_up (Nuytten et al., 2008), with an 
Enrichment Score (ES) of 0.4, contains several genes involved in differentiation, such as inbha, 
grb10 and col16a1. EZH2 (Bernstein et al., 2006) is a Polycomb protein histone 
methyltransferase promoting late-stage cancer development by silencing a specific set of genes, 
at least in part through trimethylation of associated histone H3 on Lys 27 (H3K27). It has been 
shown that EZH2 is able to maintain an undifferentiated state of neuroblastoma cells through 
epigenetic repression of the tumor suppressor gene CASZ1 (Castor Zinc finger 1). Ectopic 
restoration of CASZ1 by EZH2 silencing produces an inhibition of cell growth and an increase 
of neurite outgrowth in neuroblastoma cells (Wang et al., 2012). The enrichment plot of this 
gene set is shown in Fig. 4.11A. The gene set apoptosis_by_epoxomicin_up (ES 0.56) describes 
a set of genes that are up-regulated in SH-SY-5Y Neuroblastoma cell line after treatment with 
Epoxomicin, a protease inhibitor causing apoptosis (Concannon et al., 2007). In the gene set, 
collagen 16A1 (a main component in maintaining the integrity of the extracellular matrix), the 
elongation factor ELL2, the microtubule-associated protein 1A (map1a, which seems to have a 
fundamental role in the early events of spinal cord formation) and blc2l11 (a family member of 
the Bcl-2 family, an inducer of apoptosis) genes are all up-regulated, supporting the hypothesis 
that Epoxomicin operates inducing a stop in cell proliferation and the onset of neuronal cell 
differentiation. The enrichment plot of this gene set is shown in Fig. 4.11B. Among the gene sets 
enriched in negative phenotype, of interest is the wilms_tumor_vs_fetal_kidney pathway (ES -
0.5) (C. Li et al., 2002), in which WTs (Wilm’s Tumors) systematically overexpress genes 
corresponding to the earliest stage of metanephric development. Pax2, eya1, hbf2 and hoxa1 
encode for transcription factors that are essential for cell survival and proliferation in early 
metanephric development and repress genes corresponding to later stages of differentiation, 
suggesting in Wilm’s tumors progression a partially arrested differentiation of the blastema 
during the mesenchymal-to-epithelial transition. As well as for neuroblastoma, Wilm’s tumor 
usually occurs in early childhood and seems to have an embryonic origin, deriving from the 
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pluripotent, undifferentiated renal precursor cells. Therefore, this condition could be compatible 
with the hypothesis of an incomplete neuronal differentiation of neural crest cells in 
neuroblastoma development. The enrichment plot of the top gene set is shown in Fig. 4.11C. 
Although these results do not definitively identify mechanisms of neuronal differentiation in 
neuroblastoma cells silenced for CARM1 expression, however we identified the co-regulation at 
the transcriptome levels of genes belonging to signaling pathways involved in the fine regulation 
of neural development and neuronal differentiation, thus suggesting important new targets, 
possibly associated with CARM1 depletion, for studying the mechanisms of neuroblastoma 
pathogenesis. 
 
 
 
 
 
 
NAME FDR ES NES 
Ezh2_targets_up 0.09 0.40 22.181.787 
Apoptosis_by_epoxomicin_up 0.04 0.56 21.798.837 
Wilms_tumor_vs_fetal_kidney 0.14 -0.53 -18.860.211 
 
 
Table 4.1. The GSEA gene sets are sorted by false discovery rate (FDR<25%), from the most positive to 
the most negative, respectively. 
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Fig. 4.11. Gene Set Enrichment Analysis for SK-N-BE(2) shCARM1 cells. Shown are representative 
regulatory pathways that were ranked between the top 19 gene sets up regulated (A-B) and the 33 gene 
sets down-regulated (C) in our cellular model. 
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In conclusion, despite the very high number of DEGs obtained after microarray gene expression 
analysis on SK-N-BE(2) cells silenced for CARM1, and the wide heterogeneity in the GO terms 
extracted by DAVID analysis, we could advance the hypothesis that CARM1 could be involved 
in maintaining a neural, undifferentiated phenotype in neuroblastoma cells. We also confirmed 
our assumption by performing a qRT-PCR upon the most important target genes related to 
neuron differentiation and stemness conditions. Moreover, we took advantage by the use of 
GSEA to identify co-expressed genes in the microarray data: indeed, we identified signaling 
pathways that could be, at least partially, involved in neuroblastoma onset and progression.  
As previously reported, CARM1 is a coactivator-associated arginine methyltransferase acting 
upon a number of transcription factors and non-histone proteins through direct modification of 
histone arginines (thus providing a direct mechanism of epigenetic regulation by the modulation 
of the chromatin structure and the following accessibility to the transcriptional machinery) (see 
paragraph 2.1). Effects of CARM1 knockdown in our microarray profile suggest CARM1 as a 
fundamental player in the modulation of gene expression. Nonetheless, since shCARM1 SK-N-
BE(2) cells consist of a small amount of undifferentiated cells and a major number of (at least 
morphologically) differentiated neuronal-like cells, we reasoned that the effects of CARM1 
depletion may have become deadened by the presence of the fraction of undifferentiated cells. 
This was clearly shown by the fact that the CARM1 knockdown after infection was not at 100% 
and by the presence, as just reported, of a population of “flattened”, no neuronal-like cells, 
evidenced by the Operetta analysis. Due to all these evidences, we can speculate that CARM1 
depletion could be, at least partially, an inductor of neuronal differentiation in our cellular 
model.  
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4.4   MYCN-amplified neuroblastoma cell lines express high levels of HuB, HuC and HuD 
mRNAs compared to human fetal neural crest cells 
In order to look for neuroblastoma-specific developmental lesions which could be an effect of 
deregulated CARM1 activity, we performed transcriptome profiling of 18 neuroblastoma cell 
lines, of which 14 bearing MYCN amplification (NB69, SK-N-MC, SK-N-AS, SK-N-SH are not 
MYCN-amplified) and three primary cell lines (R1066, R1107, R113) isolated as spontaneously 
migrating neural crest cells from human fetal neural tubes, which are endowed with features of 
normal human neural crest stem cells (hNCCs) (Thomas et al., 2008). We noted that mRNA 
levels of the neuronal ELAV genes HuB, HuC and HuD, especially the first and the last, resulted 
to be much higher (until more than one hundred fold) in almost all MYCN-amplified 
neuroblastona cell lines than in hNCCs (Fig. 4.12, 4.13 and 4.14, respectively). Being HuB, HuC 
and HuD involved in the establishment of the neuronal phenotype, it can be paradoxical that 
they seem to be more expressed in MYCN-amplified neuroblastoma cells than in hNCCs. To 
investigate also the distinction between MYCN-amplified and not MYCN-amplified cells, we 
looked at the levels of MYCN expression in the whole cell panel through our transcriptome 
profiling analysis, obtaining a clear confirmation (Fig. 4.15). 
Interestingly, from the transcriptome profiling it is clear that HuD overexpression in 
neuroblastoma cell lines is not paralleled by an increase in the levels of its target p21 (Fig. 4.16). 
A way of justifying these results could be to imagine a mechanism preventing functionality of 
the neuronal ELAV proteins despite their high degree of expression in neuroblastoma cells 
compared to hNCCs. 
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Fig. 4.12. Microarray profiling of neuronal ELAV HuB mRNA levels in 18 neuroblastoma cell lines 
with respect to primary human neural crest cells (hNCCs). White bars: NB69, SK-N-MC, SK-N-AS, 
SK-N-SH neuroblastoma cell lines that do not bear a MYCN amplification. Grey bars: neuroblastoma 
cell lines bearing MYCN amplification. 
 
Fig. 4.13. Microarray profiling of neuronal ELAV HuC mRNA levels in 18 neuroblastoma cell lines 
with respect to primary human neural crest cells (hNCCs). White bars: NB69, SK-N-MC, SK-N-AS, 
SK-N-SH neuroblastoma cell lines that do not bear a MYCN amplification. Grey bars: neuroblastoma 
cell lines bearing MYCN amplification. 
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Fig. 4.14. Microarray profiling of neuronal ELAV HuD mRNA levels in 18 neuroblastoma cell lines 
with respect to primary human neural crest cells (hNCCs). White bars: NB69, SK-N-MC, SK-N-AS, 
SK-N-SH neuroblastoma cell lines that do not bear a MYCN amplification. Grey bars: neuroblastoma 
cell lines bearing MYCN amplification. 
 
Fig. 4.15. Microarray profiling of MYCN mRNA levels in 18 neuroblastoma cell lines with respect to 
primary human neural crest cells (hNCCs). White bars: NB69, SK-N-MC, SK-N-AS, SK-N-SH 
neuroblastoma cell lines that do not bear a MYCN amplification. Grey bars: neuroblastoma cell lines 
bearing MYCN amplification. 
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Fig. 4.16. ELAVL4 and p21 expression profile in neuroblastoma cell lines in comparison with primary 
human neural crest cells (hNCCs). 
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4.5 Covariance of CARM1 and nELAV proteins in neuroblastoma cell lines and potential 
activity of CARM1 on HuD 
Since ELAV proteins have been already demonstrated to be target of CARM1, we reasoned on a 
possible link between these proteins. The model was that in the onset and progression of 
neuroblastoma CARM1-induced arginine methylation of ELAV proteins would act against their 
ability to stop proliferation and induce neuronal differentiation, therefore its expression could 
arise as a compensating event to the normal induced expression of nELAV during neuroblast 
differentiation. We therefore used all our panel of 17 neuroblastoma cell lines, of which 13 
bearing MYCN amplification (we excluded the CHP126 cell line, since it is the only one 
neuroblastoma cell line growing in suspension and presenting several problems of protein 
extraction) to measure by western blotting the levels of CARM1 and of the three nELAV 
proteins by a monoclonal antibody recognizing an epitope shared by HuB, HuC, HuD but not by 
HuR. As said before, from our microarray analysis we know that the mostly expressed neuronal 
ELAV proteins in the neuroblastoma cell line panel are HuB and HuD. As reported in Fig. 4.17, 
we found that the protein levels of CARM1 and of the neuronal ELAV proteins were remarkably 
covarying (Pearson correlation coefficient of 0.89), suggesting that CARM1 increase could 
really be a neutralizing event for the activity of nELAV in neuroblastoma cells. 
Nevertheless, the above hypothesis could be reliable only if CARM1 and neuronal ELAV 
proteins can interact each other in neuroblastoma cells, being localized in the same subcellular 
compartments. While it is well known that HuD and the other nELAV proteins localize basically 
in the cytoplasm (Kasashima et al., 1999), previous reports described that CARM1 localization 
is cell-type-dependent, ranging from predominantly nuclear in HeLa cells (Frankel et al., 2002) 
to both nuclear and cytoplasmic in PC12 and C2C12 cell lines (Chen et al., 2002; Fujiwara et al., 
2006). 
Hence, to evaluate the cellular localization CARM1 and HuD, a fluorescent immunostaining of 
SK-N-BE(2) cells was performed. As clearly showed in Fig. 4.18, in SK-N-BE(2) cell line 
CARM1 (green) localizes both in the nuclei and in the cytoplasm, while HuD (red) is primarily 
cytoplasmic, confirming previous results obtained and the hypothesis of a co-localization and a 
possible interaction of HuD and CARM1 in the same compartment.  
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Fig. 4.17. Neural ELAV and CARM1 protein expression in 17 neuroblastoma cell lines. A) The whole-cell lysates 
from 17 neuroblastoma cell lines were blotted with anti-Hu PAN antibody 16A11 (Abcam) which is able to 
recognize the three neural ELAV isoforms. The immunoblot showed positive signals of variable intensity reflecting 
that all the tumor cell lines expressed neuronal specific ELAV proteins, as shown in Figure 6A (central panel). The 
same membrane was incubated with anti-CARM1/PRMT4 antibody (IMGENEX). As depicted by the image, 
CARM1 showed positive signals of variable intensities in several neuroblastoma cell lines (upper panel). B) 
Densitometric quantification showing remarkable expression of neuronal ELAV and CARM1 protein levels in 
neuroblastoma cell lines such as SK-N-MC, SKNDZ, NB69, LAN2, LAN1, CHP134, IMR32, KELLY, SK-N-
BE(2). As clearly represented in the graph, CARM1 expression level is increased in the same cell lines showing 
overexpression of neuronal ELAV protein, suggesting a possible correlation between the expression of nELAV 
protein and CARM1 in neuroblastoma cell lines. Beta tubulin was used as endogenous control. 
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Fig. 4.18. CARM1 and HuD cellular localization in SK-N-BE(2). Fluorescence immunocytochemistry 
using an anti-CARM1 (a) (green) and anti-HuD (b) (red) antibodies. Cytoplasmic localization of both 
immunoreactivities (orange) was found both in the cytoplasm of the cells (c). 
 
 
 
 
 
 
 
 73 
To further investigate the hypothesis of a CARM1-dependent nELAV-neutralizing event that 
prevent cells to undergo differentiation, a pull-down assay was performed (Figure 4.19). To this 
purpose, SK-N-BE(2) cells were transiently transfected with a pCMV6-AN-HIS-HA vector 
carrying the HuD gene and, after his-tag isolation, HuD interaction with CARM1 was verified 
by blotting the protein precipitate against CARM1. As displayed in Figure 4.19, a band at 55 
kDa in the His-tagged pull-down was detected, demonstrating CARM1 interaction with the HuD 
protein. 
 
 
Fig. 4.19. CARM1 and HuD isolation and pull down. (Mw: molecular weight; input; flow-
through (FT) and His-Tag pulldown (HIS PD). 
 
 
Experiments that demonstrate the direct correlation between HuD capability to induce neuronal 
differentiation and HuD methylation status are in progress in our laboratory. To this aim we are 
generating stable SK-N-BE(2) clones, transfecting these cells with three different vectors 
carrying HuD w/t, HuD-R236W (a ‘methyl mimetic’ form and HuD-R236K, not methylable by 
CARM1). As already done for CARM1 silenced SK-N-BE(2) cells, neuronal differentiation in 
all clones will be then evaluated both at morphological and molecular levels. If our hypothesis is 
correct, clones expressing HuD-wt and HuD-R236K should be much more differentiated 
compared to HuD-R236W clone.  
 
 
 
 74 
Finally, to test if HuD capability to stabilize its target mRNAs is directly linked to its 
methylation status, a luciferase assay has been carried out. Preliminary results (Fig. 4.20) show 
that the 3’UTR of the HuD target mRNA p21 confers a decreased translatability to the luciferase 
reporter in cells transiently overexpressing the HuD-R236W methyl mimetic plasmid. These 
results support previous data obtained by Fujiwara et colleagues (Fujiwara et al., 2006). 
Taken together, our data demonstrate a CARM1-dependent modulation of neuronal 
differentiation of SK-N-BE(2) neuroblastoma cell line. Although not demonstrated yet, we can 
speculate a CARM1 activity that works by tuning HuD methylation status; this in turn modulates 
HuD capability to bind specific mRNA targets, thus consequently reducing its neuro-
differentiative potential.  
These evidences indicate that CARM1 could be a potential druggable target in neuroblastoma 
therapy. 
 
 
 
Fig. 4.20. Reporter assay showing p21-3′ UTR–dependent luciferase translation in SKNBE(2) cells. The 
cells were co-transfected for 24 h with pGL3-p21–3′UTR- and pHA empty vector or pHA-HuD wt or 
pHA-HuD R236K or pHA-HuD R236W. Bars indicate Firefly luciferase activity normalized to Renilla 
luciferase activity. 
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Chapter 5 
Conclusions and Future Perspectives  
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Neuroblastoma is an aggressive tumor arising from the neural crest cells of the sympathetic 
nervous system (SNS) and characterized by a high grade of undifferentiation, probably due to an 
unpaired capacity of the primordial cells of the SNS to respond to signals and transcriptional 
control mechanisms operating during normal differentiation that should drive the cells to a well-
differentiated phenotype.  
Despite the use, in clinical practice, of differentiative agents able to induce differentiation of 
neuroblastoma cells, 50% of patients develop resistance or they are unresponsive to the therapy 
(Marrow, 1999). For this reason, in the last years the use of drug combinations has been 
increased, in order to produce synergistic and additive therapeutic effects.  
In this context, we focused our attention on the coactivator-associated arginine methyltransferase 
1 (CARM1), which has been shown to negatively regulate the process of neuronal differentiation 
by methylating the RNA-binding protein HuD, a known determinant of the neuronal phenotype. 
We then decided to stably silence the expression of CARM1 gene in a well-known 
neuroblastoma cell line, SK-N-BE(2), to evaluate morphological and biological differences after 
treatment of CARM1 silencing. 
Morphological differences, evaluated by the use of the high-throughput system Operetta, clearly 
demonstrated the formation of two different cell line populations in SK-N-BE(2) silenced for 
CARM1, one showing an increase in neurite outgrowth and branches and related parameters 
analyzed (maximum neurite length, total length of neurites and the number of roots for each 
cell), whereas the other maintaining a “flattened” phenotype, probably because non responding 
to CARM1 silencing. Following these results, a microarray analysis was performed in order to 
evaluate biological differences in the two systems (SK-N-BE(2) w/t versus SK-N-BE(2) silenced 
for CARM1). Several functional analysis (DAVID, GSEA) have been performed to corroborate 
our hypothesis. We were able to identify, as differentially expressed, several mRNAs involved 
in the regulation of neural development and neuronal differentiation. Furthermore, expression 
levels of several markers referred to neuronal differentiation and loss of staminality have been 
tested in qRT-PCR, which allowed us to propose an action of CARM1 upon these cells, toward 
stemness maintenance and loss of differentiation potential. 
We also took advantage by transcriptome profile that we carried out upon 18 neuroblastoma cell 
lines in order to compare expression levels of the three neuronal RNA-binding proteins HuB, 
HuC and HuD (of which 13 bearing MYCN amplification - the most important factor related to 
poor outcome in neuroblastoma) with respect to four human neural crest cells isolated as 
spontaneously migrating neural crest cells from human fetal neural tubes. We found that HuB, 
HuC and HuD are as up regulated as MYCN levels in the MYCN-bearing cells. This interesting 
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result led us to speculate that, if in neuroblastoma progression CARM1-induced arginine 
methylation of ELAV proteins inactivates their ability to induce neuronal differentiation, its 
expression could arise as a compensating event to nELAV protein appearance. This assumption 
was further strengthened by western blotting, clearly confirming CARM1 and nELAV proteins 
covariation, as well as by immunofluorescence, demonstrating a localization of CARM1 and the 
ELAV protein HuD in the same subcellular compartments. Furthermore, in order to investigate 
the possibility of a CARM1-dependent nELAV-neutralizing event preventing cells to undergo 
differentiation, a pull-down assay was performed, demonstrating CARM1 interaction with HuD. 
All these results (together with experiments aimed at demonstrating the direct correlation 
between HuD induction on neuronal differentiation and its possible methylation due to CARM1, 
in progress in our laboratory) show a CARM1-dependent modulation of differentiation in the 
SK-N-BE(2) neuroblastoma cell line. Although not formally demonstrated yet, we can speculate 
that CARM1 works by tuning nELAV methylation status, thus modulating nELAV capability to 
bind specific mRNA targets and consequently reducing its neuro-differentiative potential.  
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Supplementary data 
 
Wu’s comparison: upregulated genes agreement 
 
human 
symbol 
mouse symbol homology type wu.logFC agi.logFC 
VGLL3 Vgll3 ortholog_one2one 2.46 2.59 
IGF2 Igf2 ortholog_one2one 1.58 2.41 
PHLDB2 Phldb2 ortholog_one2one 0.683 2.18 
VAV3 Vav3 ortholog_one2one 1.01 2.13 
PHLDA1 Phlda1 ortholog_one2one 1.48 1.93 
IL11 Il11 ortholog_one2one 0.758 1.71 
SCT Sct ortholog_one2one 1.23 1.64 
CDKN1A Cdkn1a ortholog_one2one 1.29 1.61 
CDKN1A Cdkn1a ortholog_one2one 1.24 1.61 
NDRG1 Ndrg1 ortholog_one2one 1.29 1.61 
PHLDA1 Phlda1 ortholog_one2one 1.48 1.49 
DLX3 Dlx3 ortholog_one2one 1 1.49 
KIAA0513 6430548M08Rik ortholog_one2one 0.766 1.48 
ID3 Id3 ortholog_one2one 0.889 1.45 
PROM1 Prom1 ortholog_one2one 1.38 1.33 
IGF2 Igf2 ortholog_one2one 1.58 1.25 
KRT19 Krt19 ortholog_one2one 1.3 1.22 
PSTPIP1 Pstpip1 ortholog_one2one 0.601 1.19 
HERPUD1 Herpud1 apparent_ortholog_one2one 0.623 0.97 
ARID3A Arid3a ortholog_one2one 1.17 0.94 
MAPKAPK2 Mapkapk2 ortholog_one2one 1.33 0.79 
TSPAN9 Tspan9 ortholog_one2one 0.673 0.70 
HM13 H13 ortholog_one2one 0.981 0.62 
HM13 H13 ortholog_one2one 1.08 0.62 
HM13 H13 ortholog_one2one 0.675 0.62 
CDKN1A Cdkn1a ortholog_one2one 1.29 0.61 
CDKN1A Cdkn1a ortholog_one2one 1.24 0.61 
KIAA0513 6430548M08Rik ortholog_one2one 0.766 0.58 
KIAA0247 4933426M11Rik ortholog_one2one 1.32 0.57 
FLRT3 Flrt3 ortholog_one2one 1.87 0.57 
FLRT3 Flrt3 ortholog_one2one 0.86 0.57 
PFKFB4 Pfkfb4 ortholog_one2one 0.647 0.50 
LSR Lsr ortholog_one2one 0.722 0.48 
NDST1 Ndst1 ortholog_one2one 0.971 0.46 
NDST1 Ndst1 ortholog_one2one 0.767 0.46 
MAP7D1 Mtap7d1 ortholog_one2one 1.03 0.40 
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Wu’s comparison: downregulated genes agreement 
 
human 
symbol 
mouse symbol homology type wu.logFC agi.logFC 
KIT Kit ortholog_one2one -1.06 -2.00 
ELMO1 Elmo1 apparent_ortholog_one2one -0.86 -1.63 
ITPR1 Itpr1 ortholog_one2one -0.94 -1.54 
KIAA1274 X99384 ortholog_one2one -0.79 -1.37 
CDCA7L Cdca7l ortholog_one2one -1.03 -1.14 
STMN2 Stmn2 ortholog_one2one -1.06 -1.12 
JAM2 Jam2 ortholog_one2one -1.50 -1.10 
FKBP5 Fkbp5 ortholog_one2one -0.92 -0.94 
ELMO1 Elmo1 apparent_ortholog_one2one -0.86 -0.90 
RAVER2 Raver2 ortholog_one2one -1.14 -0.88 
SOX12 Sox12 ortholog_one2one -1.64 -0.80 
ZRANB3 Zranb3 ortholog_one2one -0.97 -0.78 
ZRANB3 Zranb3 ortholog_one2one -0.97 -0.75 
MRE11A Mre11a ortholog_one2one -0.84 -0.75 
PCYT1B Pcyt1b ortholog_one2one -1.24 -0.72 
CDCA7 Cdca7 ortholog_one2one -0.91 -0.72 
LRBA Lrba ortholog_one2one -0.80 -0.70 
TMPO Tmpo apparent_ortholog_one2one -0.85 -0.64 
TMPO Tmpo apparent_ortholog_one2one -1.06 -0.64 
ACP6 Acp6 ortholog_one2one -1.22 -0.64 
SMS Sms apparent_ortholog_one2one -0.84 -0.63 
PIGA Piga ortholog_one2one -0.89 -0.60 
IDE Ide ortholog_one2one -1.00 -0.54 
RFC5 Rfc5 ortholog_one2one -0.99 -0.52 
RFC5 Rfc5 ortholog_one2one -0.82 -0.52 
SMS Sms apparent_ortholog_one2one -0.84 -0.52 
NDRG2 Ndrg2 ortholog_one2one -1.53 -0.50 
RPA1 Rpa1 ortholog_one2one -0.81 -0.50 
C15orf41 BC052040 ortholog_one2one -0.77 -0.50 
PIM3 Pim3 ortholog_one2one -0.87 -0.45 
NLE1 Nle1 ortholog_one2one -0.75 -0.41 
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Wu’s comparison: discordant genes 
 
human 
symbol 
mouse symbol homology type wu.logFC agi.logFC 
ITM2A Itm2a ortholog_one2one 0.76 -3.51 
GPC3 Gpc3 ortholog_one2one 1.84 -3.12 
DLK1 Dlk1 ortholog_one2one 1.71 -3.02 
DLK1 Dlk1 ortholog_one2one 2.34 -3.02 
LGR5 Lgr5 ortholog_one2one 0.69 -2.07 
WNT6 Wnt6 ortholog_one2one 0.73 -1.94 
WNT6 Wnt6 ortholog_one2one 1.52 -1.94 
BCL2L11 Bcl2l11 ortholog_one2one 0.60 -1.43 
BCL2L11 Bcl2l11 ortholog_one2one 0.63 -1.43 
MYH10 Myh10 ortholog_one2one 0.73 -1.36 
CDKN1C Cdkn1c ortholog_one2one 1.56 -1.33 
HOXD9 Hoxd9 ortholog_one2one 1.16 -1.28 
ITM2C Itm2c ortholog_one2one 0.61 -1.27 
EPB41L5 Epb4.1l5 ortholog_one2one 0.99 -1.24 
EPB41L5 Epb4.1l5 ortholog_one2one 0.96 -1.24 
EPB41L5 Epb4.1l5 ortholog_one2one 0.79 -1.24 
PCDH1 Pcdh1 ortholog_one2one 1.00 -1.17 
PCDH1 Pcdh1 ortholog_one2one 1.24 -1.17 
PMP22 Pmp22 ortholog_one2one 1.95 -1.09 
PMP22 Pmp22 ortholog_one2one 2.17 -1.09 
MYH10 Myh10 ortholog_one2one 0.73 -1.07 
ITM2C Itm2c ortholog_one2one 0.61 -1.06 
B3GNT5 B3gnt5 ortholog_one2one 0.59 -1.05 
GATA3 Gata3 ortholog_one2one 1.25 -1.05 
MYH10 Myh10 ortholog_one2one 0.73 -1.05 
SOX11 Sox11 ortholog_one2one 0.79 -1.03 
SOX11 Sox11 ortholog_one2one 1.59 -1.03 
HOXD8 Hoxd8 ortholog_one2one 0.77 -0.92 
RAP2C Rap2c ortholog_one2one 0.76 -0.91 
PPAP2C Ppap2c apparent_ortholog_one2one 0.98 -0.85 
CABLES1 Cables1 ortholog_one2one 0.85 -0.81 
NAB1 Nab1 ortholog_one2one 0.71 -0.80 
SLC39A8 Slc39a8 ortholog_one2one 0.98 -0.79 
PRKCD Prkcd ortholog_one2one 1.16 -0.74 
RDH10 Rdh10 ortholog_one2one 0.82 -0.68 
CCNG1 Ccng1 ortholog_one2one 0.91 -0.67 
CCNG1 Ccng1 ortholog_one2one 0.80 -0.67 
HAND1 Hand1 ortholog_one2one 1.11 -0.66 
ZMYND11 Zmynd11 ortholog_one2many 0.61 -0.62 
MAGED1 Maged1 ortholog_one2one 0.63 -0.60 
IFNGR2 Ifngr2 ortholog_one2one 0.70 -0.59 
PDGFRL Pdgfrl ortholog_one2one 0.84 -0.59 
VGLL4 Vgll4 ortholog_one2one 0.90 -0.59 
INTS6 Ints6 ortholog_one2one 1.15 -0.57 
 91 
FGFR2 Fgfr2 ortholog_one2one 1.61 -0.56 
SLC19A2 Slc19a2 ortholog_one2one 0.66 -0.50 
EEF2K Eef2k ortholog_one2one 0.71 -0.50 
SYNCRIP Syncrip ortholog_one2one 0.62 -0.50 
NR1D2 Nr1d2 ortholog_one2one 0.83 -0.45 
SPTBN1 Spnb2 ortholog_one2one 0.87 -0.44 
BCL2L11 Bcl2l11 ortholog_one2one 0.60 -0.42 
BCL2L11 Bcl2l11 ortholog_one2one 0.63 -0.42 
CMTM7 Cmtm7 ortholog_one2one 0.98 -0.42 
CMTM7 Cmtm7 ortholog_one2one 1.20 -0.42 
 
DCBLD1 Dcbld1 ortholog_one2one -0.79 0.82 
TCEA3 Tcea3 apparent_ortholog_one2one -1.67 0.67 
TCEA3 Tcea3 apparent_ortholog_one2one -1.67 0.51 
 
 
 
 
